GABAA receptor subunit-related neuroanatomical substrates for attenuation of anxiety by Hellsten, Kati Susanna
 Institute of Biomedicine 
Pharmacology 
Faculty of Medicine 
University of Helsinki 
 
 
 
 
 
GABAA receptor subunit-related neuroanatomical 
substrates for attenuation of anxiety 
 
 
 
 
Kati S. Hellsten 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ACADEMIC DISSERTATION 
 
To be presented, with the permission of the Faculty of Medicine of the University of Helsinki, 
for public examination in Lecture Hall 1, Haartmaninkatu 3,  
on October 30th 2015, at 12 noon. 
 
Helsinki 2015 
Supervisors 
 
Professor Esa Korpi, MD, PhD 
Institute of Biomedicine 
Pharmacology 
Faculty of Medicine 
University of Helsinki 
 
Docent Anni-Maija Linden, PhD 
Institute of Biomedicine 
Pharmacology 
Faculty of Medicine 
University of Helsinki 
 
 
 
Reviewers 
 
Professor Garry Wong, PhD 
Faculty of Health Sciences 
University of Macau 
 
Docent Markus Storvik, PhD 
School of Pharmacy 
Faculty of Health Science 
University of Eastern Finland 
 
 
 
Dissertation opponent 
 
Docent Irma Holopainen, MD, PhD 
Clinical Pharmacology 
Department of Pharmacology, Drug Development and Therapeutics 
Faculty of Medicine 
University of Turku 
 
 
 
 
 
ISBN 978-951-51-1602-4 (paperback) 
ISBN 978-951-51-1603-1 (PDF) 
http://ethesis.helsinki.fi 
Unigrafia OY 
Helsinki 2015 
Table of contents 
 
ABSTRACT 5 
LIST OF ORIGINAL PUBLICATIONS 7 
ABBREVIATIONS 8 
1 INTRODUCTION 10 
2 REVIEW OF THE LITERATURE 12 
2.1 GABAA receptors 12 
2.1.1 Subunits and their assembly 12 
2.1.2 Binding sites 13 
2.1.3 Hyperpolarizing action 17 
2.1.4 Depolarizing action 18 
2.1.5 Synaptic GABAA receptors and phasic inhibition 22 
2.1.6 Extrasynaptic GABAA receptors and tonic inhibition 24 
2.1.7 Sources of extrasynaptic GABA 27 
2.2 Anxiety 29 
2.2.1 Locus coeruleus and anxiety 32 
2.2.2 Anxiety tests in rodents 33 
2.2.3 Neuroanatomy of conditioned fear 36 
2.2.4 Neuroanatomy of unconditioned (innate) fear 40 
3 AIMS OF THE STUDY 43 
4 MATERIALS AND METHODS 44 
4.1 Human brains (I) 44 
4.2 Experimental animals (II, III) 44 
4.3 Behavioral tests (II) 45 
4.3.1 The light : dark exploration test 45 
4.3.2 The elevated plus-maze test 46 
4.3.3 The LORR (loss of righting reflex) test 46 
4.4 Immunohistochemistry (I, III) 46 
4.4.1 Tyrosine hydroxylase (TH) immunohistochemistry (I) 46 
4.4.2 C-Fos immunohistochemistry (III) 47 
4.5 In situ hybridization (I, III) 47 
4.6 Autoradiographic binding assays (I, II, III) 49 
4.6.1 The [3H]Ro 15-4513 autoradiography (I, III) 49 
4.6.2 The [35S]TBPS autoradiography (II, III) 49 
4.7 Cell culture and transfection (II) 50 
4.8 Electrophysiology (II) 50 
4.9 Statistical analyses (II, III) 51 
5 RESULTS AND DISCUSSION 52 
5.1 Human LC neurons express GABAA receptor γ2 subunit mRNA and benzodiazepine binding sites 
(I) 52 
5.2 The Thy1α6 mouse model expresses ectopically the GABAA receptor α6 subunit contributing to 
extrasynaptic receptors and tonic inhibition 54 
5.3 Earlier behavioral characterization of consequences of ectopic expression of GABAA receptor α6 
subunits 55 
5.4 The Thy1α6 mice display an enhanced sensitivity to anxiolytic-like and sedative effects of 
gaboxadol (II) 55 
5.5 The enhanced behavioral sensitivity to gaboxadol is likely mediated via α6β3 and α6β3γ2 GABAA 
receptors 58 
5.6 GABA-insensitive [35S]TBPS autoradiographic signal reflects partial agonism of GABA (II) 59 
5.7 Highly potent GABA is a partial agonist as compared to gaboxadol in α6β3, α6β3δ and α4β3δ 
receptors but not in α6β3γ2 receptors (II) 61 
5.8 The α6 subunit-containing GABAA receptors are widely distributed in the Thy1α6 mice (III) 63 
5.9 Widespread neuronal activation associated with gaboxadol-induced anxiolysis (III) 64 
5.10 Potential mechanisms of paradoxical gaboxadol-induced widespread neuronal activation 65 
5.11 Gaboxadol activated neurons in mediodorsal thalamic nucleus only in wild-type mice 68 
6 CONCLUSIONS 69 
7 ACKNOWLEDGEMENTS 71 
8 REFERENCES 73 
9 ORIGINAL PUBLICATIONS 90 
 
 
  
 
5 
 
Abstract  
GABAergic inhibition is crucial for regulation of neuronal excitability and hence for optimal 
function of the nervous system. The GABAA receptor forms a pentameric ligand-gated anion 
channel. The subunit combinations of the receptors define their pharmacological and 
electrophysiological properties. The individual subunits display a distinct but often widespread 
distribution throughout the nervous system. GABAA receptor-mediated inhibition can be divided to 
fast and transient synaptic inhibition and to background (tonic) inhibition that is mediated by 
extrasynaptic GABAA receptors. The synaptic inhibition regulates the rhythmic activities in 
neuronal networks. Benzodiazepines, interacting with an allosteric binding site of GABAA receptors 
typically concentrated at synaptic locations, are anxiolytic drugs, but their long-term use evokes 
severe side-effects. The functional role of extrasynaptic GABAA receptor-mediated inhibition is not 
yet well understood. Expanding the understanding of local role of GABAA receptors and neuronal 
circuits mediating anxiolysis is relevant for the development of more selective and safe treatment 
for anxiety disorders. Studying the properties of extrasynaptic GABAA receptors may help to 
understand their physiological relevance and role in psychiatric and neurological disorders. 
The main objectives of this thesis were to study the local expression of benzodiazepine-sensitive 
GABAA receptors in human locus coeruleus (LC), the pharmacology of extrasynaptic GABAA 
receptors in vivo (in mice) and in vitro and the brain structures mediating acute anxiolytic responses 
in a transgenic mouse model as a consequence of enhanced tonic inhibition in specific forebrain 
structures. Firstly, the present in situ hybridization and receptor autoradiography studies in human 
LC revealed benzodiazepine binding sites indicating that LC may directly mediate the sedative 
and/or anxiolytic effects of benzodiazepines in humans. Previously, contradictory reports had been 
published in regard to the benzodiazepine binding sites in the rodent LC suggesting a potential 
species difference in the direct sites of action of benzodiazepines. Secondly, the behavioral tests 
showed that gaboxadol, a GABA site agonist, acts preferentially via extrasynaptic α6β/γ2 receptors 
in vivo as the transgenic mice overexpressing these receptors were significantly more sensitive to 
the anxiolytic and hypnotic effects of gaboxadol than the wild-type mice. Electrophysiological 
recordings on recombinant receptors revealed that GABA is a partial agonist as compared to 
gaboxadol at α6β3, α6β3δ and α4β3δ receptors but not at α6β3γ2 receptors. Gaboxadol and GABA 
displayed also different receptor desensitization and deactivation kinetics on these receptors. 
Thirdly, by increasing tonic inhibition in specific forebrain structures, the anxiolytic dose of 
gaboxadol increased c-Fos expression in the transgenic mouse model especially in the limbic areas, 
such as the cingulate cortex, septal nuclei, central extended amygdala and basolateral nucleus of 
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amygdala. In addition to demonstrating how neuronal excitability can be altered in different brain 
regions as a consequence of enhanced tonic inhibition, this result suggests that a widespread 
neuronal inhibition, as typically associated with benzodiazepines, may not be the exclusive 
mechanism of acute anxiolysis.  
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Abbreviations 
 
ACTH  adrenocorticotropic hormone  
AHN  anterior hypothalamic nucleus 
AP2  clathrin adaptor protein 2 
Best1  bestrophin 1 channel 
BLA  basolateral nucleus of amygdala 
BNST  bed nucleus of stria terminalis 
CA  carbonic anhydrase 
CAML  calcium-modulating cyclophilin ligand 
CeA  central nucleus of amygdala 
CRH  corticotropin-releasing hormone  
CS  conditioned stimulus 
dlPAG  dorsolateral part of periaqueductal gray 
DMCM  methyl-6,7-dimethoxy-4-ethyl-beta-carboline-3-carboxylate 
dmPAG  dorsomedial part of periaqueductal grey 
dmPMD  dorsomedial part of dorsal premammillary nucleus 
dmVMH  dorsomedial part of ventromedial hypothalamic nucleus 
ECl-  reversal potential of chloride ions 
EGABA-A  reversal potential of GABAA receptor 
ER  endoplasmic reticulum 
fMRI  functional magnetic resonance imaging 
GABAA  γ-aminobutyric acid A 
GABA-T  GABA-transaminase 
GAD  glutamic acid decarboxylase 
GAD  generalized anxiety disorder 
GAT  GABA transporter 
GIS  GABA-insensitive 
GnRH  gonadotropin releasing hormone  
GODZ Golgi-specific DHHC (aspartate-histidine-histidine-cysteine) zinc finger 
protein 
GTPase   guanosine triphosphatase 
HAP1  huntingtin-associated protein 1 
HPA  hypothalamic-pituitary-adrenal  
ICM  intercalated cell masses 
IL  infralimbic cortex 
KCC2  potassium-chloride co-transporter 2 
KIF5  kinesin superfamily motor protein 5 
LA  lateral nucleus of amygdala 
LC  locus coeruleus 
LORR  loss of righting reflex 
MAOB  monoamine oxidase B  
MDTB  mouse defense test battery 
MEA  medial amygdala 
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mIPSC  miniature inhibitory postsynaptic current 
mPFC  medial prefrontal cortex 
MPN  medial preoptic nucleus  
MRS  magnetic resonance spectroscopy 
NKCC1  sodium-potassium-chloride co-transporter 1 
NMDA  N-methyl-D-aspartate 
pBMA  posterior part of basomedial amygdala 
PCR  polymerase chain reaction 
PBS  phosphate-buffered saline 
pdMEA  posterodorsal part of medial amygdala  
PET  positron emission tomography 
PFC  prefrontal cortex 
PL  prelimbic cortex 
PLIC  protein linking integrin associated protein with cytoskeleton 
PMV  ventral premammilliary nucleus 
pvMEA  posteroventral part of medial amygdala 
rCBF  regional cerebral blood flow 
SAD  social anxiety disorder 
SPECT  single photon emission computed tomography 
TBPS  t-butyl-bicyclo-phosphorothionate 
TH  tyrosine hydroxylase 
TM  transmembrane 
US  unconditioned stimulus 
vlPAG  ventrolateral periaqueductal gray 
vlPMD  ventrolateral part of dorsal premammillary nucleus  
vlVMH  the ventrolateral part of ventromedial hypothalamus  
Vm  membrane potential 
VMH  ventromedial hypothalamus 
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1 Introduction 
GABAA (γ-aminobutyric acid A) receptors are ligand-gated anion channels. There are many 
different isoforms of GABAA receptors, each consisting of five subunits arranged around a central 
chloride and bicarbonate selective ion channel. The subunit arrangement of the receptor defines the 
physiological and pharmacological properties of the receptors. In adult mammalian brain, activated 
GABAA receptors typically hyperpolarize neurons, and therefore GABA is traditionally considered 
as the main inhibitory transmitter in mature brain. The agonist binding to the ligand-binding domain 
triggers a conformational change of the GABAA receptor, which results in the opening of the gate 
permitting chloride and bicarbonate ions to flow through the channel. The functional outcome of the 
GABAA receptor activation depends on the intra- and extracellular distribution of the chloride and 
bicarbonate anions and on the membrane potential of the neuron (reviewed in Farrant and Nusser, 
2005). 
GABAA receptor-mediated inhibition can be divided to fast and transient synaptic inhibition and to 
background (tonic) inhibition that is mediated by extrasynaptic GABAA receptors. An important 
function of phasic inhibition is the generation and maintaining of rhythmic activities in neuronal 
networks, such as theta and gamma frequency network oscillations associated with cognitive 
functions (Buzsáki and Chrobak, 1995). Benzodiazepine diazepam is an allosteric modulator of α1–
3 (or 5) and γ2 subunits-containing GABAA receptors, i.e. receptors typically concentrated at 
synaptic locations. The α1 subunit-containing receptors mediate diazepam-induced sedation and 
anterograde amnesia (Rudolph et al., 1999; McKernan et al., 2000), whereas the α2 subunit-
containing receptors mediate anxiolysis (Löw et al., 2000). Both α2 and α3 (and α5) subunit-
containing receptors are associated with myorelaxant effects of diazepam (Crestani et al., 2001; 
Milić et al., 2012). Tonic GABAergic inhibition is usually mediated via receptors containing α4, α5, 
α6 or δ subunits making them highly sensitive to GABA and thus suitable for detection of low 
GABA concentrations (Brickley et al., 1996; Farrant and Nusser, 2005; Lee and Maguire, 2014). 
Although not yet well understood, tonic GABAA receptor-mediated inhibition may play an 
important role in physiological functions as well as in psychiatric and neurological disorders 
(Belelli et al., 2009; Egawa and Fukuda, 2013). The pharmacological investigations of extrasynaptic 
GABAA receptors may help to understand their physiological relevance and role in psychiatric and 
neurological disorders. 
Anxiety disorders are the most frequent mental disorders in the contemporary EU countries, 
Switzerland, Norway and Iceland estimated to affect 14% of population across all age groups 
11 
 
(Wittchen et al., 2011). Anxiety disorders are pharmacologically treated by benzodiazepines but the 
adverse effects such as dependence, tolerance, drowsiness and impairment of cognition limit their 
use in chronic anxiety disorders (Millan, 2003; Farb and Ratner, 2014). Selective serotonin reuptake 
inhibitors and serotonin/noradrenaline reuptake inhibitors are currently used as the first-line 
pharmacological treatment of anxiety disorders, but many individuals are not responsive to these 
drugs and their adverse effects such as nausea, dizziness and sexual problems can also limit their 
use (Millan, 2003; Farb and Ratner, 2014). Expanding the understanding of the pharmacology and 
local roles of GABAA receptors and the neuronal circuits mediating anxiolysis is relevant for the 
development of more selective and safe treatment for anxiety disorders.  
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2 Review of the literature 
2.1 GABAA receptors 
2.1.1 Subunits and their assembly 
GABAA receptors are ligand-gated anion channels. The GABAA receptors belong to the 
superfamily of the Cys-loop pentameric ligand-gated ion channels. Each subunit of the receptors in 
this superfamily consists of a long N-terminal extracellular hydrophilic region, followed by four 
transmembrane (TM) segments and ending with a relatively short extracellular C-terminal domain. 
The TM2 segment forms the lining of the ion channel, and there is a large intracellular loop 
between the TM3 and TM4 segments (Olsen and Sieghart, 2009). Two cysteine residues spaced by 
13 amino acids form the cysteine loop at the N-terminal extracellular domain of the GABAA 
receptor (Korpi et al., 2002a) (Figure 1). 
 
Figure 1. A. Each GABAA receptor subunit contains an N-terminal extracellular hydrophilic region, four 
transmembrane segments (TM) and short extracellular C-terminal domain. The cysteine loop (C-C) locates 
at the N-terminal extracellular domain of each subunit. B. The TM2 domain (2) of each subunit of the 
pentameric receptor forms the wall of the ion channel. The majority of native GABAA receptors are 
composed of two α, two β and one γ subunit. 
There are many different isoforms of GABAA receptors, each consisting of five subunits 
surrounding a central chloride and bicarbonate selective ion channel. The subunit arrangement of 
the receptor defines its physiological and pharmacological properties. The individual subunits 
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display a distinct but often widespread distribution throughout the nervous system varying in their 
regional, cellular and sub-cellular localization. Therefore they have different roles in brain circuits 
and behaviors. Currently 19 subunits of GABAA receptor are known; α1–6, β1–3, γ1–3, δ, ε, θ, π 
and ρ1–3, and an alternative splicing contributes to an additional receptor diversity (reviewed in 
Uusi-Oukari and Korpi, 2010; Olsen and Sieghart, 2008; Rudolph and Knoflach, 2011). The 
homopentameric GABAA receptors consisting of ρ subunits have sometimes been called GABAC 
receptors because they are insensitive to bicuculline (blocks response to GABA in other GABAA 
receptors) and baclofen (stimulates metabotropic GABAB receptors), but the Nomenclature 
Committee of the International Union of Pharmacology (IUPHAR) has recommended not to use 
GABAC nomenclature for such receptors (Barnard et al., 1998; Bormann, 2000).  
The receptor subunit assembly takes place in the endoplasmic reticulum (ER). Unassembled or 
improperly folded receptor subunits are subject to degradation and are not targeted to the cell 
surface (Luscher et al., 2011). Based on the current knowledge, it has been estimated that more than 
800 distinct GABAA receptor subtypes may exist in the brain. Subunit-specific antibodies have 
revealed that receptors composed of α1β2γ2 subunits are the most abundant GABAA receptors in 
the brain (Olsen and Sieghart, 2009). 
2.1.2 Binding sites  
GABAA receptors contain different binding sites for different types of ligands. The GABA and 
benzodiazepine binding sites are located at extracellular regions of the GABAA receptors whereas 
barbiturates, neurosteroids and alcohol have been suggested to bind mostly to the TM regions of the 
receptors. Picrotoxin and TBPS (t-butyl-bicyclo-phosphorothionate) bind to the channel pore (Korpi 
et al., 2002a). Below is a more detailed review of the binding sites and the respective ligands that 
are the most relevant for this thesis. 
GABA binding site. As revealed mostly by studies on recombinant receptors, the GABA binding 
site has been located at the interface of α and β subunits. The amino acid residue Phe64 of the α1 
subunit forms part of the functional GABA binding site (Sigel et al., 1992; Smith and Olsen, 1994 
and 1995; Boileau et al., 1999). This amino acid has been proposed to contribute to a low-affinity 
binding site for GABA (Baur and Sigel, 2003). Also other amino acids (Arg66, Ser68, Arg120, 
Val178, Val180 and Asp183) of the α1 subunit have been associated with the low-affinity GABA 
binding site at the extracellular N-terminus of the GABAA receptor (Boileau et al., 1999; Westh-
Hansen et al., 1999; Newell and Czajkowski, 2003). A conformational variant of the low-affinity 
binding site has been proposed to form a high-affinity binding site for GABA (Smith and Olsen 
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1994; Newell et al. 2000; Baur and Sigel., 2003). Alternatively, the high-affinity GABA binding 
site has been proposed to locate at a different subunit interface, separate from the low-affinity 
binding site (Newell et al., 2000). Nevertheless, the affinity of GABA to the binding site is largely 
dependent on the type of α subunit in the receptor complex (Hevers and Lüddens, 1998). The α6 
subunit-containing receptors are the most sensitive to GABA with EC50 values of 0.2-2 μM (Ducic 
et al., 1995; Knoflach et al., 1996; Saxena and Macdonald, 1996), whereas in α3 subunit-containing 
receptors the EC50 value for GABA is approximately ten or hundred times higher (Sigel et al., 1990; 
Ebert et al., 1994; Verdoorn, 1994). GABA has an intermediate affinity to the α1, α2, α4 or α5 
containing GABAA receptors (Wafford et al., 1993; Ebert et al., 1994; Knoflach et al., 1996). 
GABAA receptors containing the δ subunit are ten times more sensitive to GABA than receptors 
containing the γ subunit (Saxena and Macdonald, 1996; Hevers et al., 2000; Brown et al., 2002). In 
addition, GABA has higher affinity to αβ receptors than to αβγ (Sigel et al., 1990; Horne et al., 
1993). 
Also several GABA analogs bind to the GABA binding site. Muscimol has been regarded as a 
substance that can activate all GABAA receptor subtypes (Krogsgaard-Larsen et al, 1979). In early 
autoradiographic experiments, [3H]muscimol was used to label GABA binding sites (Olsen et al., 
1990). However, low concentrations (10 nM) of [3H]muscimol appeared to reveal only a fraction of 
all GABAA receptors as the binding signal was not as widely distributed as after radioactively 
labelled benzodiazepine or channel site ligands (Korpi et al., 2002a). This high-affinity 
[3H]muscimol binding has been associated with α6 and δ subunits in cerebellum and with α4 and δ 
subunits in the forebrain, as the high-affinity [3H]muscimol binding was reduced in the cerebellar 
and forebrain sections of the δ-deficient mice (Chandra et al., 2010; Korpi et al, 2002b; Mihalek et 
al., 1999), in the forebrain of α4-knock-out mice (Chandra et al., 2010) and in the cerebellar 
sections of the α6-knock-out mice (Mäkelä et al., 1997). Chandra et al. (2010) studied also the 
motor performance of several mutant mice by fixed speed rotarod after an i.p. injection of muscimol 
at doses estimated to become bioavailable at nanomolar concentrations in mouse brains. The α4- 
and δ-deficient mutant mice displayed a decreased behavioral sensitivity to muscimol as compared 
to their wild-type controls although recombinant receptors have been paradoxically reported to 
exhibit unaltered binding affinities to [3H]muscimol in the presence or absence of the δ-subunit 
(Hevers et al., 2000). The α1-knock-out mice had an unaltered behavioral sensitivity to muscimol as 
well as an unaltered high-affinity [3H]muscimol binding (Chandra et al., 2010). The transgenic 
Thy1α6 mice overexpressing the α6 subunit in the forebrain including hippocampus and cerebral 
cortex showed an increased high-affinity [3H]muscimol binding in these brain regions and had an 
increased behavioral sensitivity to muscimol (Chandra et al., 2010).  
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Muscimol has been used as a model substance to design several other GABA analogs, such as 
gaboxadol (Krogsgaard-Larsen et al., 2004). Also gaboxadol is a GABA-site agonist (Karobath and 
Lippitsch 1979; Wafford et al., 1996; Ebert et al., 1997), and the regional distribution of high-
affinity binding of [3H]gaboxadol resembles that of [3H]muscimol in the rat brain (Friemel et al., 
2007) as it acts preferentially via α4 and δ subunit-containing GABAA receptors in the brain (Belelli 
et al. 2005; Cope et al. 2005;  Jia et al. 2005; Chandra et al. 2006; Storustovu and Ebert 2006; 
Winsky-Sommerer et al. 2007, Meera et al., 2011). Although gaboxadol has been shown to be less 
potent (EC50 13 μM) than GABA (EC50 0.35 μM) or muscimol (EC50 0.20 μM) at recombinant 
human α4β3δ receptors, it has been shown to be more efficient (Emax 224%) than GABA (Emax 98%) 
or muscimol (Emax 120%) at these receptors (Mortensen et al., 2010). Native α4 and δ subunit-
containing GABAA receptors on thalamic neurons (Chandra et al. 2006; Herd et al. 2009) as well as 
α6 and δ subunit-containing GABAA receptors on cerebellar granule cells were shown to be 
responsive to sub-micromolar concentrations of gaboxadol, and such gaboxadol sensitivity required 
the δ subunit (Meera et al., 2011). In addition, gaboxadol has been reported to be a partial agonist at 
α1 subunit-containing receptors such as α1βγ2 receptors and a full agonist at α2 containing 
receptors as compared to GABA (Ebert et al., 1994; Ebert et al., 1997; Wafford and Ebert, 2006). 
Ionophore binding site. The ionophore binding site of the GABAA receptor is also called a 
convulsant site or an ion channel site. Binding of compounds such as picrotoxinin and [35S]TBPS to 
the ionophore binding site, block the chloride ion flow through the GABAA receptor ion channel 
and cause convulsions (reviewed in Korpi et al., 2002a). The exact binding sites of these 
compounds are not known. It has been suggested that although picrotoxinin and [35S]TBPS possibly 
bind to the same site of the GABAA receptor, they may have different structural requirements. 
Electrophysiologically detected picrotoxinin block has been reported in homomeric receptors 
composed of α, β, γ, δ and ρ subunits and in heteromeric receptors of αβ, βγ, αγ and αβγ 
combinations. [35S]TBPS binding has been detected in homomeric β receptors and in heteromeric 
αβ, βγ and αβγ combinations but not in homomeric α or γ receptors or in heteromeric receptors 
composed of αγ subunits (reviewed in Sieghart et al., 1995). Electrophysiological recordings have 
revealed that TBPS can block also homopentameric ρ receptors (Vale et al., 1999). Picrotoxin (an 
equimolar mixture of picrotoxinin and picrotin) has been proposed to interact with Val257 of ion 
channel lining TM2 residue of rat α1 subunits (Xu et al., 1995). In β3 subunits, Ala252 and Leu253 
of TM2 have been proposed to be important for picrotoxin and TBPS affinity (Buhr et al., 2001), 
and Val251, Ala252 and Leu253 of TM2 have been proposed to be important for the formation of a 
high-affinity binding site for TBPS (Jursky et al., 2000).  
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Benzodiazepine binding site (zolpidem, flumazenil, diazepam, Ro 15-4513). Benzodiazepine site 
ligands modulate allosterically GABA-induced currents via GABAA receptors only in the presence 
of GABA. The high-affinity benzodiazepine binding site is located at the interface between α and γ 
subunits (Sigel and Buhr, 1997; Ernst et al., 2003). The type of β subunit present in these receptors 
is not likely to significantly modulate the benzodiazepine action. Benzodiazepine site ligands may 
also interact with receptors containing γ1 or γ3 instead of γ2 subunits with different 
pharmacological profiles (Wafford et al., 1993; Sieghart, 1995; Hevers and Luddens, 1998; Khom 
et al., 2006).  
Ro 15-4513 exhibits high affinity to all GABAA receptors consisting of αβγ subunit combinations 
(reviewed in Sieghart, 1995). It usually acts as a partial inverse agonist at the benzodiazepine sites 
(Bonetti et al., 1988; Hadingham et al., 1993; Korpi et al., 2002a). However, Ro 15-4513 is an 
agonist in α4/6βγ2 receptors (Bonetti et al., 1988; Knoflach et al., 1996) and it has a slight positive 
modulatory effect in α2β1γ1 receptors (Wafford et al., 1993). Flumazenil (Ro 15-1788) is a 
benzodiazepine site competitive antagonist that binds to the same GABAA receptor subunit 
combinations as Ro 15-4513 (Sieghart, 1995). 
Diazepam has a comparable affinity and efficacy at α1βγ2, α2βγ2, α3βγ2 and α5βγ2 subunit 
combinations (Sieghart, 1995; Hevers and Luddens, 1998), but α4βγ2 and α6βγ2 receptors are 
diazepam-insensitive (Wisden et al., 1991; Wieland et al., 1992; Luddens et al., 1995). It has been 
shown that the amino acid arginine at the position 99 and 100 of the α4 and α6 subunit, 
respectively, plays an important role in their insensitivity to diazepam (the equivalent amino acid is 
histidine in the other α variants) (Wieland et al., 1992; Korpi et al., 2002a). Substituting the arginine 
of the α6 subunit by histidine made the receptor sensitive to diazepam, whereas substituting the 
histidine at the homologous position 101 by arginine in the α1 subunit, made the α1 subunit-
containing receptors insensitive to diazepam (Wieland et al., 1992). In a study by Benson et al. 
(1998), it was shown that the replacement of the conserved histidine residue of α1, 2, 3 and 5 by 
arginine (H101R, H101R, H126R and H105R, respectively) resulted in diazepam-insensitivity of 
the respective αβ2/3γ2-receptors. Furthermore, Ro 15-4513 acted as an agonist at these mutant 
receptors.  
Diazepam-sensitive receptors contain zolpidem-sensitive and -insensitive receptors (Luddens et al., 
1995). Zolpidem binds with high affinity to α1βxγ2 GABAA receptors and GABAA receptors 
containing γ1 or γ3 subunits exhibit little to no zolpidem sensitivity (Luddens et al., 1994; Sanna et 
al., 2002). Zolpidem has a low affinity to GABAA receptors containing α2 or α3 subunits, and 
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receptors containing the α5 subunit are nearly zolpidem-insensitive (Pritchett and Seeburg, 1990; 
Luddens et al., 1995; Sieghart, 1995).  
Furosemide binding site. Furosemide does not cross the blood-brain barrier (Seelig et al., 1994), 
and therefore it does not bind to the brain GABAA receptors in vivo. In vitro, furosemide has been 
shown to antagonize the function of α6 and β2/3 subunits containing GABAA receptors, and the 
effect was demonstrated to be independent of the presence of γ or δ subunits (Korpi and Luddens, 
1997). Furosemide sensitivity was shown to involve the amino acid isoleucine at the position 228 in 
TM 1 of the α6 subunit, but also other residues were likely to be involved (Thompson et al., 1999). 
The α4β3γ2 receptor was shown to be less sensitive to furosemide than the α6β3γ2 receptor, but it 
was more than 50-fold more sensitive than receptors containing other α subunits, i.e. α1β3γ2, 
α2β3γ2, α3β3γ2 or α5β3γ2 (Wafford et al., 1996). The action of furosemide has also been shown to 
be dependent on the β-subunit type, being weaker at β1-containing receptors than at β2- or β3-
containing receptors (Korpi et al., 1995).  
2.1.3 Hyperpolarizing action  
In adult mammalian brain, activated GABAA receptors typically hyperpolarize neurons, and 
therefore GABA is traditionally considered as the main inhibitory transmitter in mature brain. The 
agonist binding to the ligand-binding domain triggers a conformational change of the GABAA 
receptor, which results in the opening of the gate permitting chloride and bicarbonate ions to flow 
through the channel. The functional outcome of the GABAA receptor activation depends on the 
intra- and extracellular distribution of the chloride and bicarbonate anions and on the membrane 
potential of the neuron (Farrant and Nusser, 2005). A hyperpolarizing GABA response might not be 
inhibitory if it indirectly triggers hyperpolarization-activated depolarizing mechanism (Kaila et al., 
1997; Farrant and Nusser, 2005). 
In most mature neurons, the activity of the potassium-chloride co-transporter KCC2 that extrudes 
chloride ions from the neuron to the extracellular space causes a chloride equilibrium potential that 
is more negative than the resting membrane potential (Figure 2). In contrast, the equilibrium 
potential for bicarbonate is more positive than the resting membrane potential (Farrant and Nusser, 
2005). However, chloride ions are much more permeable than bicarbonate ions. It has been 
estimated that the relative bicarbonate/chloride permeability of GABAA receptors ranges between 
0.18 and 0.6 (Fatima-Shad and Barry, 1993). Consequently, GABAA receptor activation typically 
results in a net influx of anions, causing hyperpolarizing inhibitory postsynaptic potential (IPSP) 
and decreasing the probability of an action potential initiation (Farrant and Nusser, 2005).  
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2.1.4 Depolarizing action 
GABAA receptor-mediated currents may also be depolarizing. Depolarizing responses can be 
generated by activated GABAA receptors in an immature brain. At early stages of development 
GABAergic signals act as an important source of excitatory drive and modulate neuronal migration 
and circuit formation (reviewed in Ben-Ari and Spitzer, 2010). High intracellular chloride 
concentration leads to chloride ion efflux via the GABAA receptor channels once activated.  During 
prenatal and early postnatal life, hippocampal and cortical neurons display positive reversal 
potential of chloride ions (ECl–) relative to membrane potential (Vm) as a result of robust activity of 
NKCC1 (sodium-potassium-chloride co-transporter) but a minimal activity of KCC2 (potassium-
chloride co-transporter) (Ben-Ari et al., 2012). NKCC1 is driven by sodium gradient and 
accumulates intracellular chloride ions whereas chloride ion efflux is mediated largely by KCC2 
driven by potassium gradient (Figure 2). The spike threshold differs in different immature neurons 
and therefore GABA may depolarize some neurons and excite others. For instance, GABA has been 
reported to depolarize pyramidal neurons and interneurons in both deep and superficial layers of the 
immature neocortex, but to generate action potentials only in deep layers (L5/6) but not in 
superficial layers (L2/3) because L5/6 pyramidal cells have more depolarized resting potentials and 
more hyperpolarized threshold of action potential generation (Rheims et al., 2008). If the spike 
threshold is above the reversal potential of GABAA receptor (EGABA-A), GABAergic depolarization 
can trigger activation of voltage-gated currents that may enable to reach the spike threshold (Ben-
Ari et al., 2012).  Depolarizing GABAA receptor-mediated currents have also been reported in 
embryonic rat spinal and olfactory bulb cells (Serafini et al., 1995). 
A negative shift in the ECl– relative to Vm  is associated with a robust increase in KCC2 expression, a 
decrease in functional activity of NKCC1 and with hyperpolarizing GABAA currents (Ben-Ari, 
2002, Ben-Ari and Spitzer, 2010; Ben-Ari et al., 2012).  In addition to the hippocampus and cortex 
a significant increase in the activity of KCC2 has been reported in mature retina, cerebellum and 
dorsal horn of the spinal cord as compared to that at birth (Ben-Ari et al., 2012).  
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Figure 2. The NKCC1 and KCC2 expression-dependent shift from GABAA receptor-mediated depolarization 
to hyperpolarization. In certain immature neurons, a robust activity of the chloride importer NKCC1 
(sodium-potassium-chloride cotransporter) but a minimal activity of the chloride exporter KCC2 (potassium-
chloride cotransporter) is present. In adult neurons the hyperpolarizing GABAA receptor mediated currents 
are associated with a robust increase in KCC2 expression and a decrease in functional activity of NKCC1 
leading to a lower intracellular accumulation of chloride in mature neurons and to chloride ion influx as a 
result of GABAA receptor activation (modified from Ben-Ari et al., 2012). 
Depolarizing and excitatory responses can be generated by GABAA receptor activation also in a 
mature brain. Initially, depolarizing responses were recorded in hippocampal pyramidal cells when 
GABA or pentobarbitone was applied to their dendrites. GABAA receptors located at the dendritic 
tree were suggested to be depolarizing whereas those in the cell body or close to it were expected to 
be hyperpolarizing (Alger and Nicoll, 1979; Andersen et al., 1980). A few years later, Alger and 
Nicoll (1982) reported that GABA elicited hyperpolarizing responses in CA1 pyramidal cells when 
applied to the soma, but primarily depolarizing responses when applied to the apical dendrites, 
although hyperpolarizing responses were also recorded. They concluded that hyperpolarizing 
responses reflected the activation of synaptic receptors, which were highly concentrated on the 
pyramidal cell soma/initial segment, but that these receptors were also present on the dendrites. The 
depolarizing responses evoked in the dendrites were proposed to reflect the activation of 
extrasynaptic receptors (Alger and Nicoll, 1982). In adult hypothalamic gonadotropin releasing 
hormone (GnRH) neurons, GABAA receptors have been reported to exert both depolarizing and 
hyperpolarizing effects and the most recent studies indicate that the predominant action of 
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endogenously released GABA is excitation in slice preparations of adult hypothalamic GnRH 
neurons (Herbison and Moenter, 2011).  
GABAA receptor-mediated depolarizing responses have been reported in several in vitro studies in 
adult guinea pig and rat hippocampus (Wong and Watkins, 1982; Michelson and Wong, 1991; 
Lambert et al., 1991; Xie and Smart 1993). The depolarizing postsynaptic response as a result of 
tetanic stimulation of the adult hippocampal GABAergic interneurons has been shown to be more 
effective in triggering spikes than the simultaneously activated glutamatergic inputs. In line with the 
finding, blockade of the GABAA receptors alleviated rather than promoted neuronal excitability 
(Taira et al., 1997). It was proposed that high-frequency stimulation mimicking the in vivo firing 
frequencies of GABA-releasing interneurons, and any other condition that increased the open time 
of the GABAA receptor, depolarized the postsynaptic membrane because the electrochemical 
gradient for chloride ions collapsed more significantly than that for bicarbonate ions (Staley et al., 
1995). An intraneuronal carbonic anhydrase (CA) was proposed to compensate the bicarbonate 
efflux by regenerating bicarbonate of CO2 that diffused across the membrane after being released 
from the extracellular bicarbonate ions. Intra- and extracellular pH buffers were binding and 
releasing, respectively, hydrogen ions for the process. It was shown that in rat hippocampal slices 
an intense stimulation of GABAA receptors on the distal dendrites produced a hyperpolarizing 
membrane potential response followed by a slow depolarizing potential that was 20 mV positive to 
the resting membrane potential (Staley et al., 1995). The phenomenon was proposed to occur 
because the intracellular chloride ion concentrations could change significantly in small structures 
such as in dendrites and therefore reduce the driving force for chloride whereas in larger structures 
the ionic gradients were more stable (Qian and Sejnowski, 1990). Also the voltage-dependent 
magnesium ion block of the N-methyl-D-aspartate (NMDA) receptor was proposed to be 
preferentially lessened in those dendrites with the most intense GABAA receptor activation resulting 
in higher membrane depolarization (Staley et al., 1995). 
Later on, a new theory on the mechanism of GABA-mediated depolarization was presented (Figure 
3). It involved GABAergic extracellular potassium ion transients ([ K+]o) causing an inward 
potassium ion current that induced a long-lasting and a more positive membrane potential than 
EGABA-A in spite of a positive shift in EGABA-A (Kaila et al., 1997; Smirnov et al., 1999; Viitanen et 
al., 2010). It was proposed that in rat hippocampus, GABAA receptor-mediated excitation was 
dependent on bicarbonate efflux via GABAA receptor channels. Bicarbonate efflux caused 
depolarization that drove an equal influx of chloride ions via the GABAA receptor channel. This 
intracellular accumulation of chloride ions activated extrusion of chloride and potassium ions by 
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KCC2, thereby giving rise to a transient increase in the extracellular potassium concentration. The 
intracellular bicarbonate levels did not fall during its efflux phase because CA regenerated 
bicarbonate using CO2 as a substrate. Bulk electroneutrality was maintained without a 
transmembrane cation influx since H+ ions were produced in the hydration reaction of CO2 at the 
same rate as bicarbonate ions. These H+ ions were bound by cytoplasmic buffers to maintain the 
intracellular pH (Viitanen et al., 2010).  It was also postulated that the bicarbonate-dependent 
increase in [K+]o did not  affect only the postsynaptic neurons but it also had a depolarizing 
influence on all nearby neurons, glial cells and presynaptic terminals, therefore having a non-
synaptic nature (Smirnov et al., 1999). 
 
 
Figure 3. Illustration of the ionic mechanism of the GABAA receptor-dependent increase in [K+]o. The 
HCO3− efflux via GABAA receptors causes depolarization that drives uptake of Cl− into the neuron. Carbonic 
anhydrase (CA) provides an intracellular source of HCO3− during its efflux from intracellular water and 
CO2. The bulk electroneutrality of the neuron is maintained without a transmembrane cation flux because H+ 
and HCO3− ions are produced at the same rate in the hydration reaction of CO2. The intracellular pH is 
maintained because cytoplasmic buffers bind these H+ ions. The HCO3−-driven intraneuronal accumulation 
of Cl− activates extrusion of Cl− by KCC2, giving rise to a K+ efflux and thereby to an increase in [K+]o 
(modified from Viitanen et al., 2010). 
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More recently it has been proposed that the local intra- and extracellular chloride concentrations and 
hence the direction of chloride flux via GABAA receptors are determined by negatively charged 
impermeant intra- and extracellular macromolecules rather than by the function of KCC2 and 
NKCC1 (Glykys et al., 2014a). However, the cation-chloride transporters were considered critically 
important for restoring intracellular chloride concentrations and volume after signaling transients 
(Glykys et al., 2014b). 
2.1.5 Synaptic GABAA receptors and phasic inhibition  
Transient activation of synaptic GABAA receptors represents phasic type of GABAergic inhibition. 
An action potential at the nerve terminal triggers the presynaptic vesicles to fuse with the 
presynaptic membrane and to release GABA into the synaptic cleft (Figure 4). It has been estimated 
that each vesicle contains several thousand GABA molecules and an action potential generates high 
(a millimolar range) peak GABA concentration in a synaptic cleft. Miniature inhibitory 
postsynaptic currents (mIPSCs) are rapid and occur spontaneously when GABA is released from a 
single synaptic vesicle and activates nearly synchronously a proportion of the GABAA receptors in 
the underlying postsynaptic density. An action potential of the presynaptic neuron may trigger a 
synchronous or asynchronous release of multiple vesicles and an activation of GABAA receptors at 
adjacent postsynaptic densities within the same synaptic bouton. Currents that result from GABA 
spillover and activation of extrasynaptic receptors can be considered phasic if they are temporally 
linked to the GABA vesicle release event (Farrant and Nusser, 2005). An important function of 
phasic inhibition is the generation and maintaining of rhythmic activities in neuronal networks, such 
as theta and gamma frequency network oscillations associated with cognitive functions (Buzsáki 
and Chrobak, 1995).  
It has been proposed that ten to a few hundred GABAA receptors are clustered to the postsynaptic 
membrane (Farrant and Nusser, 2005). Synaptic GABAA receptors contain typically the γ2 subunit 
together the α1, α2, or α3 subunits and any β subunits (Brünig et al., 2002; Korpi and Sinkkonen, 
2006) (Figure 4) although no GABAA receptor subunit is known to be exclusively located at 
synaptic membranes. The mechanism by which GABAA receptors are delivered to and maintained 
at synapses is poorly known and many proteins have been postulated to play a role in targeting and 
stabilizing GABAA receptors at the postsynaptic density (Farrant and Nusser 2005). Gephyrin has 
been proposed to play a role in stabilizing GABAA receptors at postsynaptic sites (Cherubini and 
Conti, 2001; Möhler et al., 2002; Lüscher and Keller, 2004), and this role may be receptor subtype-
specific (Lüscher et al., 2011). Gephyrin interacts with microtubules and with several regulators of 
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microfilament dynamics (Kirsch and Betz, 1995; Mammoto et al., 1998). When GABAA receptors 
leave the area containing postsynaptic scaffold proteins, they become highly mobile and diffuse 
along the plane of the phospholipid bilayer (Lüscher et al., 2011). 
The number of GABAA receptors in the postsynaptic membrane controls the efficacy of phasic 
inhibition. This is regulated by GABAA receptor subunit gene expression and subunit assembly, 
receptor exocytosis, diffusion, endocytosis, recycling and degradation (reviewed in Lüscher et al., 
2011). GABAA receptor subunits assemble in ER involving an interaction with ER-associated 
chaperones (Lüscher et al., 2011). Unfolded or improperly folded subunits are ubiquitinated and 
degraded in proteasomes (Lüscher et al., 2011). Also chronic blockage of neural activity enhances 
ER-associated degradation (Lüscher et al., 2011). An interaction of α and β subunits with ubiquitin-
like protein PLIC (protein linking integrin associated protein with cytoskeleton) inhibits their 
ubiquitination and promotes the exit of receptors from the ER to the Golgi  (Lüscher et al., 2011). In 
the Golgi, the cytoplasmic cysteines of γ2 subunits are palmitoylated by the Golgi resident 
palmitoyltransferase [Golgi-specific DHHC zinc finger protein (GODZ)], which promotes the 
receptor translocation to the plasma membrane and synapses (Lüscher et al., 2011). Reduced 
expression of GODZ has been shown to reduce the number of GABAA receptors at synapses and 
the amplitude and frequency of mIPSCs and whole cell currents (Fang et al., 2006).  
GABAA receptors are removed from the cell surface by endocytosis through clathrin-coated 
vesicles (Tehrani and Barnes, 1993; Kittler et al., 2000) that are specialized sites on the plasma 
membrane of eukaryotic cells responsible for the internalization of many cell-surface receptors and 
other membrane proteins (Gaidarov et al., 1999). The endocytosis occurs via interaction of GABAA 
receptor β and γ subunits with the clathrin adaptor protein AP2 after which the complex interacts 
with other binding partners including clathrin, guanosine triphosphatase (GTPase) dynamin and its 
binding partner amphiphysin (Kittler et al., 2000; Lüscher et al., 2011). Phosphorylation of β 
(S408/409 in β3) and γ (Y365/367 in γ2) subunits interferes with these interactions and stabilizes 
the receptors at plasma membrane. Endocytosed receptors that are ubiquitinated at γ2 subunits are 
targeted to lysosomal degradation whereas those interacting with a calcium-modulating cyclophilin 
ligand (CAML) and huntingtin-associated protein 1 (HAP1) at γ2 and β subunit, respectively, are 
recycled back to plasma membrane by kinesin superfamily motor protein 5 (KIF5) -dependent 
vesicular transport. (Lüscher et al., 2011). 
The efficacy of synaptic GABAergic transmission is regulated also by changes in GABA release 
and uptake (Farrant and Nusser 2005). GABA release can be modulated by receptors for GABA or 
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other neurotansmitters on presynaptic terminals or on astrocytes (Cherubini and Conti, 2001; Kang 
et al., 1998). It has been proposed that GABA activates astrocytic GABAB receptors triggering 
glutamate release from astrocytes and increasing GABA release when glutamate activates the 
presynaptic glutamate receptors (Kang et al., 1998). GABA is cleared from the synaptic cleft by 
diffusion and by the action of plasma membrane GABA transporters (GATs). Diffusion is 
influenced by the viscosity of the synaptic cleft liquid, geometry of the cleft and the surrounding 
extrasynaptic space, and by the localization of receptors and GATs (Cherubini and Conti, 2001). 
High-affinity GATs are located in the presynaptic neurons and astrocytes, although neuronal uptake 
has been estimated to be three to six-fold more efficient than glial uptake (Madsen et al., 2008). 
GATs are capable of bidirectional neurotransmitter transport and their function is highly dependent 
on extracellular Na+ and to a lower extent on the Cl- ions. The driving force for GABA transport 
against its concentration gradient is supplied by the movement of Na+ down its concentration 
gradient. Following the GABA uptake into the presynaptic neuron, the transmitter is preferentially 
recycled directly into synaptic vesicles being readily available for further release (Cherubini and 
Conti, 2001; Madsen et al., 2008). Alternatively, GABA taken up into axon terminals may enter a 
so called GABA shunt which is a closed-loop process producing and conserving the supply of 
GABA. First, GABA is metabolized by GABA-transaminase (GABA-T) to succinic semialdehyde 
that is further metabolized by succinic semialdehyde dehydrogenase to succinic acid entering the 
tricarboxylic acid cycle (Krebs cycle) for oxidative metabolism and resulting in α-ketoglutarate. 
The α-ketoglutarate is then transaminated into glutamate that is decarboxylated by glutamic acid 
decarboxylase (GAD) back to GABA that can then re-enter the process (Olsen and DeLorey 1999; 
Madsen et al., 2008) (Figure 4). In glia, GABA is metabolized to succinic semialdehyde by GABA-
T but GABA cannot be resynthesized by GAD in this compartment since glia lack GAD. In glia 
GABA can be converted to glutamine, which is transferred back to the neuron, in which glutamine 
is converted to glutamate by glutaminase, which re-enters the GABA shunt (Figure 4). Therefore, it 
has been postulated that GABA that is taken up by glia is not immediately available for synaptic 
transmission (Olsen and DeLorey 1999; Cherubini and Conti, 2001).  
2.1.6 Extrasynaptic GABAA receptors and tonic inhibition  
Some GABAA receptors do not accumulate at postsynaptic membranes. These extrasynaptic 
receptors with a high affinity for GABA mediate tonic inhibition providing a persistent conductance 
(Stell and Mody, 2002, Semyanov et al., 2004; Farrant and Nusser, 2005; Glykys and Mody, 2007). 
The persistent hyperpolarizing current generated by extrasynaptic GABAA receptors makes the 
neuron less likely to generate an action potential (Pavlov et al., 2009). The α4, α5, α6, and δ 
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subunits are predominantly localized extrasynaptically or perisynaptically (Farrant and Nusser, 
2005) (Figure 4), but their subcellular distribution may vary between cell types. The δ subunit has 
been localized in the cortex, hippocampus, thalamus, striatum, and cerebellum (Lee and Maguire 
2014). In cerebellar granule cells as well as in hippocampal dentate gyrus granule cells, the δ 
subunit has been shown to be localized exclusively outside the postsynaptic density (Nusser et al., 
1998; Wei et al., 2003). The δ subunit forms receptors specifically with the α6 and β2/3 subunits in 
cerebellar granule cells and with the α4 and βx subunits in the forebrain (Barnard et al., 1998). The 
α6 subunit expression is almost entirely limited to the cerebellum, whereas the α4 subunit is highly 
expressed in the thalamus, hippocampus, striatum, and cortex (Lee and Maguire 2014). In thalamus, 
extrasynaptic α4βδ GABAA receptors mediate tonic conductance in ventrobasal nuclei, medial 
geniculate body and dorsal lateral geniculate nucleus (Cope et al., 2005; Jia et al., 2005; Richardson 
et al., 2013). The α5 (and γ2) subunit-containing receptors are highly expressed in the hippocampus 
and to lower extent in the cortex, olfactory bulb, and hypothalamus (Olsen and Sieghart, 2009; Lee 
and Maguire 2014). 
Tonic GABAergic currents have been recorded in the basolateral (BLA) and lateral (LA) nuclei of 
amygdala (Marowsky et al., 2012). The α3 subunit protein was moderately expressed in the LA and 
strongly in the BLA, mainly at extrasynaptic sites (Marowsky et al., 2012). In α3 knock-out mice, 
tonic currents were significantly reduced in BLA principal cells, but not in LA principal cells 
(Marowsky et al., 2012). An α3-selective GABAA receptor agonist (TP003) increased tonic currents 
and dampened excitability markedly in BLA principal cells of wild-type mice but not in those of α3 
knock-out mice (Marowsky et al., 2012). Also interneurons of the LA and BLA expressed a tonic 
current, but the α3-selective GABAA receptor agonist potentiated these currents only in a small 
fraction of these neurons (Marowsky et al., 2012). In the central nucleus of amygdala (CeA), tonic 
GABAergic inhibition was mediated by α1 or δ subunit-containing receptors depending on the 
neuronal subpopulation (Herman et al., 2013).  
In hypothalamus, GnRH neurons release GnRH to regulate fertility by controlling the release of 
follicle-stimulating hormone and luteinizing hormone from the anterior pituitary. In the brain slice 
preparation, half of the GnRH neurons displayed tonic GABAA receptor current that was associated 
with δ subunit-containing GABAA receptors (Bhattarai et al., 2011). These tonically active GABAA 
receptors may be important in controlling the reproductive function as in GnRH neuron-specific 
conditional γ2 subunit knock-out mice no effects on fertility, estrous cycles, puberty onset, or 
luteinizing hormone levels were observed although the amplitude and frequency of postsynaptic 
IPSCs were decreased (Lee et al., 2010a). A tonic GABAergic conductance that was enhanced by 
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blocking the activity of glial GATs has been reported also in the magnocellular neurosecretory cells 
within the supraoptic nucleus of the hypothalamus (Park et al., 2006). It has been proposed that this 
tonic conductance is mediated via α5βγ2 receptors and to a lesser extent by δ-containing receptors 
(Jo et al., 2011).  
The extrasynaptic α4βδ GABAA receptors in ventrobasal nuclei have been associated with the 
hypnotic/sedative action of etomidate and gaboxadol (Belelli et al., 2005; Chandra et al., 2006; 
Herd et al., 2009), but also other  drugs have been proposed to alter the tonic inhibition in the brain 
(Brickley and Mody, 2012) (Table 1). 
Table 1. Drugs altering the tonic GABAergic inhibition in the brain (modified from Brickley and Mody, 
2012). 
Drug Mechanism of action 
 
Current drug indications 
Vigabatrin 
 
Irreversible block of GABA 
transaminase raising ambient GABA 
levels. 
Refractory complex partial seizures and 
infantile spasms. Not favored due to 
visual field loss in some adults and 
children. 
Tiagabine  Blockade of GABA transporters on 
nerve terminals (predominantly GAT-1) 
raising ambient GABA levels. 
Partial seizures; generalized anxiety 
disorders/panic disorders.  
Gaboxadol Selective agonist at extrasynaptic 
GABAA receptors leading to specific 
enhancement of the tonic conductance. 
Sleep enhancer, but withdrawn from 
phase III clinical trials due to poor risk-to-
benefit ratio (hallucinations and 
disorientation in a subset of patients). 
L-655,708 High-affinity negative allosteric 
modulator of α5 subunit-containing 
GABAA receptors reducing tonic 
conductance. 
Cognitive enhancer but not suitable for 
human use due to anxiogenic properties.  
Ganaxolone Positive allosteric modulator of most 
GABAA receptors with greater 
potency/efficacy at δ subunit-containing 
GABAA receptors leading to selective 
enhancement of the tonic conductance. 
Catamenial epilepsy.  
Alphaxalone  Positive allosteric modulator of most 
GABAA receptors with greater 
potency/efficacy at δ subunit-containing 
GABAA receptors leading to selective 
enhancement of the tonic conductance. 
Anesthetic and sedative in long-term 
intensive care patients that was withdrawn 
from clinical practice due to 
complications with the vehicle, 
Cremophor EL. Widely used as an 
anesthetic in veterinary surgery. 
Propofol  Positive allosteric modulator of most 
GABAA receptors including α5 or δ 
subunit-containing GABAA receptors 
leading to enhanced tonic conductance. 
Widely used as an intravenous anesthetic. 
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2.1.7 Sources of extrasynaptic GABA 
Under physiological conditions, GABA spillover from the synaptic cleft after vesicular fusion is 
likely the main source of extrasynaptic GABA (Glykys and Mody, 2007) (Figure 4). Tonic 
inhibition increases when GABA transporter subtypes 1 and 3 (GAT-1 and GAT-3) are 
pharmacologically blocked (Rossi et al., 2003; Keros and Hablitz, 2005) and in GAT-1 knockout 
mice (Jensen et al., 2003). There are also additional non-vesicular sources of extrasynaptic GABA, 
as tonic inhibition occurs also if vesicular GABA release is blocked (Rossi et al., 2003; Wu et al., 
2003). Under certain conditions, neuronal and glial plasma membrane transporters (GAT-1 – GAT-
3) can reverse their action and release GABA from neurons or glial cells (Richerson and Wu 2003; 
Koch and Magnusson, 2009) (Figure 4). The direction of operation is dependent on the Na+ ions, 
the difference in GABA concentration between the intra- and extracellular space and on the 
membrane potential (Koch and Magnusson, 2009). GABA can be released from astrocytes by the 
reverse action of glial GAT subtypes GAT-2 or GAT-3 induced by glutamate uptake (Héja et al. 
2012). Recently it has been reported that in striatum and cerebellum GABA is synthesized in glia 
from putrescine via monoamine oxidation by monoamine oxidase B (MAOB) (Yoon et al., 2014). 
The glial GABA is released via bestrophin 1 channels (Best1) (Figure 4) and contributes to tonic 
inhibition in hippocampus, cerebellum and striatum (Le Meur et al., 2012; Lee et al., 2010b; Yoon 
et al., 2011; Yoon et al., 2014). Also a release from dying cells or non-vesicular leakage may 
provide extrasynaptic GABA (Glykys and Mody, 2007). Ca2+-dependent retrograde release of 
GABA from dendritic structures has been reported in olfactory granule cells, interneurons in 
thalamic relay nuclei, layer 2/3 neocortical bitufted interneurons and in the principal neurons of the 
lateral superior olive (Koch and Magnusson, 2009). 
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Figure 4. Sources of synaptic and extrasynaptic GABA (black dots) activating synaptic and extrasynaptic 
GABAA receptors and contributing to phasic and tonic inhibition, respectively.  Following the GABA uptake 
into the presynaptic neuron by GABA transporter (GAT), GABA may be recycled directly into synaptic 
vesicles being readily available for further release or enter the GABA shunt. In GABA shunt GABA is first 
metabolized by GABA-transaminase (GABA-T) to succinic semialdehyde that is further metabolized to 
succinate entering the tricarboxylic acid cycle (Krebs cycle) (dashed circular arrow) for oxidative 
metabolism and resulting in α-ketoglutarate. The α-ketoglutarate is then transaminated into glutamate that is 
decarboxylated by glutamic acid decarboxylase (GAD) back to GABA that can then re-enter the process. In 
glia, uptaken GABA can be first converted to glutamate that is then converted to glutamine. Glutamine is 
transferred back to the neuron, in which glutamine is converted to glutamate that re-enters the GABA shunt. 
The main source of extrasynaptic GABA is GABA spillover from the synaptic cleft after vesicular fusion. 
Under certain conditions, neuronal and glial GATs can reverse their action and release GABA from neurons 
or glial cells. GABA can also be synthesized in glia from putrescine by monoamine oxidase B (MAOB), and 
it is released via bestrophin 1 channels (Best1). Synaptic GABAA receptors contain typically the γ2 subunit 
with α1, α2, or α3 subunits and any β subunits, whereas the α4, α5, α6, and δ subunits are predominantly 
localized extra- or perisynaptically. The α5 subunits form extrasynaptic receptors with γ2 subunits but not 
with δ subunits. 
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2.2 Anxiety  
According to ICD-10 (International Statistical Classification of Diseases and Related Health 
Problems 10th Revision), anxiety disorders include agoraphobia, social phobia, specific phobias, 
panic disorder and generalized anxiety disorder (GAD) (Table 2). In 2010, anxiety disorders were 
the most frequent mental disorders in the contemporary EU countries, Switzerland, Norway and 
Iceland estimated to affect 69.1 million persons (14.0%) across all age groups (Wittchen et al., 
2011). Anxiety disorders have typically an early onset, are often of chronic or recurrent nature, 
cause substantial personal distress, impair the ability to function socially and occupationally, 
increase the suicidal thoughts and behavior, and impose a substantial economic burden (Baldwin et 
al., 2013). Fear and anxiety overlap in anxiety disorders, but they are distinct phenomena (Grillon, 
2007). Fear is an adaptive component of the acute stress response to potentially dangerous stimuli 
and is characterized by a flight or fight response (Millan, 2003; Grillon, 2007). In the sensation of 
anxiety, fear becomes disproportional in intensity, chronic and/or irreversible, or not associated 
with any genuine risk (Millan, 2003).  Anxiety is characterized by tension, worry, negative affect 
and a feeling of insecurity and it is associated with avoidance and increases in overall sensory 
sensitivity (Grillon, 2007).  
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Table 2. Main anxiety disorders and their description according to ICD-10 (International 
Statistical Classification of Diseases and Related Health Problems 10th Revision).  
 
 
Phobic anxiety disorders 
Anxiety evoked in certain well-
defined situations that are not 
currently dangerous. These 
situations are characteristically 
avoided or endured with dread. The 
patient's concern may be focused 
on individual symptoms like 
palpitations or feeling faint and is 
often associated with secondary 
fears of dying, losing control, or 
going mad. Contemplating entry to 
the phobic situation usually 
generates anticipatory anxiety. 
Agoraphobia 
A fairly well-defined cluster of phobias embracing fears of leaving 
home, entering shops, crowds and public places, or travelling alone in 
trains, buses or planes. Panic disorder is a frequent feature of both 
present and past episodes. Avoidance of the phobic situation is often 
prominent. 
Social phobias 
Fear of scrutiny by other people leading to avoidance of social 
situations. More pervasive social phobias are usually associated with 
low self-esteem and fear of criticism. They may present as a complaint 
of blushing, hand tremor, nausea, or urgency of micturition, the patient 
sometimes being convinced that one of these secondary manifestations 
of their anxiety is the primary problem. Symptoms may progress to 
panic attacks. 
Specific (isolated) phobias 
Phobias restricted to highly specific situations such as proximity to 
particular animals, heights, thunder, darkness, flying, closed spaces, 
urinating or defecating in public toilets, eating certain foods, dentistry, 
or the sight of blood or injury. Though the triggering situation is 
discrete, contact with it can evoke panic as in agoraphobia or social 
phobia. 
 
 
 
Other anxiety disorders 
 
Disorders in which manifestation 
of anxiety is the major symptom 
and is not restricted to any 
particular environmental situation. 
Depressive and obsessional 
symptoms, and even some 
elements of phobic anxiety, may 
also be present, provided that they 
are clearly secondary or less 
severe. 
Panic disorder  
The essential feature is recurrent attacks of severe anxiety (panic), 
which are not restricted to any particular situation or set of 
circumstances and are therefore unpredictable. As with other anxiety 
disorders, the dominant symptoms include sudden onset of 
palpitations, chest pain, choking sensations, dizziness, and feelings of 
unreality (depersonalization or derealization). There is often also a 
secondary fear of dying, losing control, or going mad.  
Generalized anxiety disorder 
Anxiety that is generalized and persistent but not restricted to, or even 
strongly predominating in, any particular environmental circumstances 
(i.e. it is "free-floating"). The dominant symptoms are variable but 
include complaints of persistent nervousness, trembling, muscular 
tensions, sweating, lightheadedness, palpitations, dizziness, and 
epigastric discomfort. Fears that the patient or a relative will shortly 
become ill or have an accident are often expressed. 
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The anxiety disorders are treated by benzodiazepines but the adverse effects limit their use in 
chronic anxiety disorders (Millan, 2003; Farb and Ratner, 2014). The short-term benefits of 
benzodiazepines are well known, but their long-term use causes dependence, daytime somnolence, 
blunted reflexes, memory impairment, and an increased risk of falls in older people (Mugunthan et 
al., 2011). Selective serotonin reuptake inhibitors and serotonin/noradrenaline reuptake inhibitors 
are currently used as the first-line pharmacological treatment of anxiety disorders but many 
individuals are not responsive to the treatment and the side effects such as nausea, dizziness and 
sexual problems of these drugs are often limiting their use (Millan, 2003; Farb and Ratner, 2014). 
Other pharmacological treatments of anxiety disorders include tricyclic antidepressants (inhibit 
serotonin and noradrenaline reuptake but have also affinity on different receptors), buspirone 
(serotonin1A receptor agonist), pregabalin (reduces the synaptic release of several neurotransmitters 
by binding to voltage-gated calcium channels), noradrenaline reuptake inhibitors and the α2-
adrenergic agonist (clonidine) (Bandelow et al., 2014; Itoi and Sugimoto, 2010).  
A better understanding of neurocircuitry and molecular pathways mediating anxiety is required for 
the development of more selective and safe treatment for anxiety disorders (Millan, 2003; Farb and 
Ratner, 2014). Brain-imaging methods in humans have revealed the involvement of the amygdala 
and prefrontal, insular, limbic, paralimbic, and occipital cortices as well as the basal ganglia in 
anxiety (Farb and Ratner, 2014). These imaging methods include the functional Magnetic 
Resonance Imaging (fMRI) that reveals changes in regional cerebral blood flow (rCBF) that is a 
marker of energy consumption by neurons. Both excitatory and inhibitory neurotransmission are 
energy-consuming processes and cause changes in rCBF (Detre and Floyd, 2001). Magnetic 
resonance spectroscopy (MRS) is a noninvasive technique monitoring the levels of neurochemicals 
in the brain (Farb and Ratner, 2014). The positron emission tomography (PET) involves a systemic 
exposure to a short-lived radioactive tracer. It has been used to study metabolism, receptor binding, 
and alterations in regional blood flow within certain brain areas, but it lacks a resolution for 
structural details and is a highly costly technique (Politis and Piccini, 2012). The single photon 
emission computed tomography (SPECT) is another emission tomography technique using a 
radionucleotide-labeled tracer but it has lower resolution than PET (Bailey and Willowson, 2013). 
To be complemented with clinical findings, animal tests of anxiety are crucial for biomedical 
research, including testing of anxiolytic drugs, assessment of behavioral phenotypes of mutant and 
transgenic animals, testing neurobiological hypotheses and finding candidate genes for anxiety 
disorders (Kalueff and Nutt, 2007).  
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2.2.1  Locus coeruleus and anxiety 
The locus coeruleus (LC) is the largest noradrenergic nucleus producing half of the total 
noradrenaline in the brain (de Lecea et al., 2012). LC projects virtually to all brain regions with the 
exception of basal ganglia (Sara, 2009). The adrenergic receptors are G-protein-coupled receptors 
that modulate neuronal excitability via distinct G-protein-coupled signal cascades. There are three 
major categories of adrenergic receptors, α1, α2 and β, each eliciting different cellular responses. 
Each category is further divided into subtypes. It has been suggested that the effect of noradrenaline 
in any brain region is complex and depends on the intracellular concentration of noradrenaline and 
the receptor subtypes in the target region (Sara, 2009). LC mediates the alarm reaction during stress, 
and its over-activity increases the arousal level and amplifies emotional reactions to stress 
(Yamamoto et al., 2014).  
Noradrenergic dysfunction has been associated with anxiety disorders (Yamamoto et al., 2014), 
although a causal relationship has not been demonstrated (Itoi, 2008). However, the activation of 
LC by direct electrical stimulation or by pharmacologic agents has elicited fear responses in 
primates whereas such responses have been reduced by decreasing LC firing (Southwick et al., 
1999). In addition, noradrenaline reuptake inhibitors and the α2-adrenergic agonist (clonidine) are 
used as a pharmacological treatment for anxiety disorders, whereas the α2-adrenergic antagonist 
(yohimbine) has been shown to increase anxiety symptoms (Itoi and Sugimoto, 2010; Itoi, 2008).  
LC-mediated responses to stress are linked to the neuroendocrine stress system by corticotropin-
releasing hormone (CRH) (reviewed in Kovács, 2013). Activation of the hypothalamic-pituitary-
adrenal (HPA) axis is a well-known mediator of neuroendocrine stress responses, but in addition to 
stimulating the release of adrenocorticotropic hormone (ACTH), also known as corticotropin, and 
glucocorticoids from the pituitary gland and adrenal cortex, respectively, CRH from the 
paraventricular nucleus of hypothalamus increases the firing of TH-positive neurons in LC. LC 
receives CRH-positive afferents also from the brainstem, Barrington nucleus, CeA and bed nucleus 
of stria terminalis (BNST). Different stressors recruit different CRH pathways projecting to LC. As 
an example, psychosocial stress increases CRH mRNA levels in the CeA and BNST (Kovács, 
2013). 
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2.2.2 Anxiety tests in rodents 
Numerous preclinical anxiety tests have been developed for animals (Griebel and Holmes, 2013) 
(Table 3). One major difficulty confronted in animal studies on anxiety is the absence of concrete 
parameters reflecting the emotional component of anxiety. Surrogate markers, such as an increase 
in arterial pressure, tachycardia, hyperthermia and excessive secretion of glucocorticoids into the 
systemic circulation, can be instructive in the evaluation of anxiety, but behavioral end-points such 
as avoidance, escape, freezing are generally preferred although their precise relevance to different 
types of anxiety disorders in man is not easy to determine (Millan 2003). The translational value of 
an animal test in understanding pathological anxiety in humans can be assessed by three validity 
criteria; face, predictive and construct validity (Griebel and Holmes, 2013). Face validity 
determines if the test measures something analogous to one or more human anxiety symptoms. 
Predictive validity defines whether the test is reliably sensitive to clinically efficacious anxiolytics. 
Construct validity determines if the test measures something analogous to one or more mechanisms 
of human anxiety disorder (Griebel and Holmes, 2013). None of the currently available anxiety tests 
or models is considered unequivocally meet these criteria (Griebel and Holmes, 2013). 
 
 
 
 
 
 
 
 
 
 
 
34 
 
Table 3. Commonly used anxiety tests in experimental rodents and the anxiety disorders they are proposed 
to model (Griebel and Holmes, 2013; Parsons and Ressler, 2013; Bourin et al., 2007). In bold are 
highlighted the most frequently used animal tests in anxiety research between 1990 and 2011 (Haller et al., 
2013). 
Procedure Group Principle Test Anxiety 
disoder 
Unconditioned Approach-
avoidance 
conflict tests 
Generation of a conflict between 
a drive to approach novel areas 
and a simultaneous avoidance of 
potential threat therein. 
Open?field test, 
elevated plus?
maze test, 
light/dark 
exploration test 
Generalized 
anxiety 
disorder, 
specific phobias 
Fear tests Testing mice for their responses 
(fight, flight, freeze, vocalize or 
scan) to an approaching 
anaesthetized natural predator. 
Mouse Defense 
Test Battery 
(MDTB) 
Generalized 
anxiety 
disorder, panic 
disorder 
Interaction- 
based tests 
Measuring the time spent by 
pairs of rodents in social 
interaction (e.g. sniffing, 
following or grooming the 
partner). 
Active social 
interaction 
(unfamiliar rat 
pairs), resident 
intruder, ultrasonic 
vocalization 
(separation 
induced) 
Generalized 
anxiety 
disorder, social 
anxiety disorder 
 
Conditioned Conditioned 
fear tests 
Learning process in which a 
neutral stimulus as a result of 
pairing with fear-provoking 
stimulus becomes a conditioned 
stimulus (CS) that alone elicits 
fear. Fear extinction is learning 
that the CS no longer predicts the 
unconditioned stimulus. 
Pavlovian fear 
conditioning 
Specific 
phobias and 
other anxiety 
disorders 
 Conflict?
based tests 
Measuring anxiolytic?like 
activity via the maintenance of a 
behavioral response despite the 
receipt of a punishment (mild 
electric shock). 
Vogel conflict test, 
Geller?Seifter test 
Generalized 
anxiety disorder 
Unconditioned anxiety tests, especially the elevated plus-maze, light/dark and open-field tests, are 
easy, quick and inexpensive to perform and analyze and are therefore popular in preclinical drug 
testing and genetic research (Blanchard et al., 2008). The elevated plus-maze, light/dark and open-
field tests generate a conflict between the natural drive to approach novel areas and an avoidance of 
a potential threat there, and are considered to model especially specific phobias and GAD (Griebel 
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and Holmes, 2013). The social interaction test of anxiety is thought to mimic the state of anxiety in 
GAD and social anxiety disorder (SAD) (File and Seth, 2003; Griebel and Holmes, 2013). The test 
measures the time spent by pairs of rodents in social interaction (e.g. sniffing, following or 
grooming the partner) (File and Seth, 2003). The test conditions (the light intensity and the novelty 
of the test arena) can be manipulated to generate different levels of anxiety (File and Seth, 2003). 
The Mouse Defense Test Battery (MDTB) provides multiple measures related to fear and anxiety. 
In the test, mice are placed in an oval runway and tested for their fight, flight, freeze, vocalize or 
scan responses to a natural predator (Griebel and Holmes, 2013). Predator-elicited flight responses 
in mice have been suggested to serve as an experimental model of panic attacks (Griebel et al., 
1996). 
In fear conditioning an emotionally neutral stimulus is paired with an aversive unconditioned 
stimulus (US). As a result of the pairing, the neutral stimulus becomes a conditioned stimulus (CS) 
that alone elicits fear. If the CS is subsequently presented repeatedly in the absence of the US, it 
gradually loses the ability to elicit fear. This phenomenon, i.e. learning that the CS no longer 
predicts the US, is called extinction (LeDoux, 2000, Sotres-Bayon et al., 2004; Johansen et al., 
2011). The Pavlovian fear conditioning test and its variations are considered as useful models to 
study the neural circuitry and the cellular and molecular mechanisms of fear-related disorders as 
anxiety disorders are thought result from a dysregulation of normal fear learning mechanisms 
(Dunsmoor and Paz, 2015). Early life experience and genetic background are important risk factors 
in the development of fear-related disorders (Parsons and Ressler, 2013). When an individual 
experiences a traumatic event, the person learns to fear the cues that are associated with the 
traumatic event, and this fear memory is transferred from short-term memory into long-term 
memory (Parsons and Ressler, 2013). The psychopathology of anxiety disorders is characterized by 
recruitment of cues not originally associated with the traumatic event (a phenomenon called 
generalization) and by sensitization to fear experiences when an exposure to fear cues occurs 
(Parsons and Ressler, 2013). It has been demonstrated that a similar brain activation pattern is 
observed in humans and rodents in a fear conditioning test, and that these areas are notably 
dysregulated in anxiety disorders suggesting a promising face and construct validity of the test 
(Parsons and Ressler, 2013).  
Other types of conditioned procedure tests include the Vogel conflict and Geller-Seifter tests that 
measure anxiolytic-like activity as the maintenance of a behavioral response despite the receipt of a 
mild electric shock (Griebel and Holmes, 2013). In the Vogel conflict test water-deprived rodents 
are exposed to a mild and intermittent electric shock via a water bottle whereas in the Geller-Seifter 
36 
 
conflict test, rats that are trained to respond for a food reward are exposed to a modest electric 
shock during a “conflict” component of the procedure (Millan, 2003). Vogel conflict test and other 
fear-based conflict tests are postulated to be relevant for testing anxious states related to GAD, 
social and other phobias, but their validity in reflecting other anxious states, such as those related to 
panic attacks is less apparent (Millan, 2003). .   
Despite of a large number of existing preclinical anxiety tests, preferences for their use have not 
changed between the years 1990 and 2011 (Haller et al., 2013). The elevated plus-maze test was 
used in half of all anxiety studies identified in a thorough Medline search, and the elevated plus-
maze, open-field, social interaction, and light/dark box tests accounted for about 80% of them 
(Haller et al., 2013). The most widely used animal tests of anxiety have been argued to predict only 
a specific type of anxiolytic activity (Haller et al., 2013). Actually, about 40% of compounds that 
have been promising in preclinical tests were ineffective in clinical trials. The important difference 
between the anxiety disorders and anxiety-like behavior monitored by classical preclinical animal 
tests is that anxiety disorders are chronic states with “excessive” or “unreasonable” fear whereas the 
animal tests often monitor acute manifestations of natural fears. The mechanisms mediating the 
non-pathological extreme forms of anxiety are essential for survival and likely to be highly 
conserved in different mammalian species (Steimer, 2001). As certain compounds have been shown 
to reduce both natural fear responses and symptoms of anxiety disorders, the mechanisms 
underlying these natural and “unreasonable” fears are probably overlapping.  However, as some 
substances selectively reduce only the natural fear responses or the symptoms of anxiety disorders, 
their mechanisms are not identical (Haller et al., 2013).  
An important component of anxiety disorders is linked to personality characteristics. An inhibited 
(fearful) temperament, i.e. trait anxiety, is supposed to be a predisposing factor for anxiety disorders 
(Steimer, 2011). Therefore trait anxiety animal models including genetic models, chronic exposure 
to fear-provoking stimuli, rodent strains displaying high or low anxiety and inter-individual 
differences within a defined strain model may be critical tools for scientists trying to unravel the 
mechanisms of these complex disorders (Steimer, 2011). 
2.2.3 Neuroanatomy of conditioned fear  
Amygdala has been implicated in the acquisition, expression and extinction of conditioned fear 
(LeDoux, 2000). During the acquisition phase, pathways transmitting the conditioned auditory 
stimulus and unconditioned nociceptive stimulus were proposed to be transmitted to the lateral 
nucleus of amygdala (LA) serving as a sensory input region (LeDoux, 2000). Expression of 
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conditioned fear was proposed to involve changes in the activity of the LA and in CeA to which LA 
is connected both directly and indirectly via the basal and accessory basal nuclei and intercalated 
cell masses (ICM) (LeDoux, 2000, Sotres-Bayon et al., 2004; Johansen et al., 2011). During 
contextual fear conditioning, the acquisition phase was proposed to involve the hippocampus and 
the communication between the ventral hippocampus (CA1 and subiculum) and the basal and 
accessory basal nuclei of amygdala that project further to the CeA (LeDoux, 2000). According to 
the theory by LeDoux, CeA serves as an output region of both acoustic and contextual CSs and 
controls the expression of fear responses by sending projections to the hypothalamus and brainstem 
(LeDoux, 2000, Sotres-Bayon et al., 2004; Johansen et al., 2011).  
Indeed, many animal studies involving lesions, pharmacological manipulations and electrical 
stimulation support the central role of amygdala in the acquisition and expression of conditioned 
fear. Post-training and pre- or post-training lesions of CeA and BLA, respectively, blocked fear-
potentiated startle to both auditory and visual CSs in rats (Campeau and Davis, 1995). 
Pharmacological inactivation of the prelimbic cortex (PL) reduced conditioned fear expression 
(Corcoran and Quirk, 2007). As PL projects to BLA, PL may augment conditioned fear responses 
via this pathway (Milad and Quirk 2002). Infusion of muscimol into BLA and LA either before 
conditioning training or before testing the responses to CS (tone or context) decreased the freezing-
response to the conditioned stimuli (Muller et al., 1997). Pharmacological blockage of NMDA 
receptors in the rat BLA or CeA prior to fear conditioning training abolished the acquisition of both 
auditory and contextual fear conditioning (Goosens and Maren, 2003). Infusions of muscimol into 
CeA and LA resulted in an impairment of acquisition of conditioned fear further suggesting that 
also CeA is involved in fear learning and is not a simple output structure (Wilensky et al., 2006). As 
a result, the fear circuitry theory by LeDoux was updated to involve also CeA as an input station for 
CS and US resulting in memory formation of conditioned fear. However, it still remained unsolved 
whether plasticity and memory formation in CeA occurred in parallel to that in LA or if it relied on 
distributed plasticity throughout the amygdala that was initiated by LA neurons (Wilensky et al., 
2006). Recent developments in methodologies have made it possible to study how fear memories 
are acquired at the circuitry level. An in vivo study in mice using implanted chronic recording 
electrodes and optogenetic and pharmacological approaches has shown that inactivation of lateral 
subdivision of the CeA during the acquisition phase of fear conditioning interfered with the learning 
process indicating that excitation of neurons in the lateral subdivision of the CeA is required for fear 
acquisition (Ciocchi et al., 2010). It was further shown that the conditioned freezing behavior was 
driven by excitation of output neurons in the medial subdivision of CeA (Ciocchi et al., 2010). In 
the lateral subdivision of CeA some neurons exhibited CS-evoked short-latency excitatory 
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responses, whereas some displayed a strong inhibitory response and the majority did not exhibit any 
CS-evoked responses (Ciocchi et al., 2010).  
Many studies suggest that amygdala has a role also in fear extinction. Like other types of learning, 
extinction learning can be divided into acquisition, consolidation, and retrieval phases (Quirk and 
Mueller, 2008). Acquisition is the initial phase of extinction learning in which conditioned 
responses are declining within an extinction training session. In the consolidation phase, 
physiological and molecular processes stabilize a long-term extinction memory. In the retrieval 
phase of extinction, a presentation of the extinguished CS triggers a retrieval of extinction, 
characterized by low levels of conditioned responding.  
Blockade of NMDA (Sotres-Bayon et al., 2007) or metabotropic glutamate subtype 1 (Kim et al., 
2007) receptors within the BLA has been reported to impair the acquisition of fear extinction. Also 
the ventrolateral periaqueductal gray (vlPAG) has been proposed to mediate extinction acquisition 
as the acquisition of extinction was impaired in rats with naloxone-blocked μ-opioid receptors in the 
vlPAG (McNally et al., 2004, 2005). Noradrenergic action within the BLA has been proposed to 
enhance the consolidation of conditioned fear extinction (Berlau and McGaugh, 2005). Several 
molecular processes have been identified within the amygdala (BLA), hippocampus and prefrontal 
cortex (PFC) during the consolidation of extinction (Quirk and Mueller, 2008). 
PFC is poorly developed in rodents as compared to humans, and it consists of the orbital frontal, 
anterior cingulate, infralimbic (IL) and prelimbic (PL) cortices in rodents (Sotres-Bayon et al., 
2004). Selective stimulation of IL during a CS session facilitates fear extinction (Milad and Quirk, 
2002; Vidal-Gonzalez et al., 2006). It has been shown that CS-evoked firing of IL neurons increases 
during fear extinction training and this firing is larger a day after the extinction training when rats 
are recalling extinction (Milad and Quirk 2002). Rats with lesions in IL extinguish freezing 
responses within a CS session but display excessive freezing to the CS the following day, 
suggesting impaired recall of extinction (Quirk et al. 2000; Lebron et al. 2004).  
There are also marked deficits in fear extinction when intercalated cells of amygdala (ITC) are 
injured (Likhtik et al., 2008). The ITC cells receive a strong projection from IL, and potentiated 
activity of IL during extinction retrieval could inhibit amygdala output via activation of ITC cells 
(Quirk and Muller, 2008). This is supported by the finding that electrical stimulation of IL reduces 
the responsiveness of CeA output neurons to BLA stimulation (Quirk et al, 2003). In contrast to IL, 
stimulation of PL has been shown to slower the rate of fear extinction and to prevent extinction 
learning (Vidal-Gonzalez et al., 2006).  
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Hippocampus is proposed to play an important role in the fear extinction of contextual CS (Sotres-
Bayon et al., 2004, Quirk and Mueller, 2008; Maren et al., 2013). Hippocampus sends mainly 
glutamatergic projections from CA1/subiculum to mPFC (primarily to IL and ventral PL), and may 
regulate CeA output via mPFC or via its connections with basal and accessory basal nuclei of 
amygdala (Sotres-Bayon et al., 2004). It has been proposed that the activation of CeA through the 
direct glutamatergic projection from the hippocampus to BLA as well as through the indirect BLA 
activation via the glutamatergic projection to PL may be crucial for the renewal of fear expression 
in response to an extinguished conditional stimulus (Figure 5) (Maren et al., 2013). In contrast, 
hippocampus may indirectly inhibit the CeA firing via its glutamatergic projection to IL that further 
sends glutamatergic projections to ITC and thus can activate the inhibitory GABAergic projections 
from ITC to CeA (Maren et al., 2013). This inhibition of CeA output is involved in suppressing the 
expression of fear in response to an extinguished conditional stimulus (Maren et al., 2013). 
 
Figure 5. The neural circuit involved in the context-dependent regulation of fear memory involves the 
hippocampus, infralimbic cortex (IL), prelimbic cortex (PL), basolateral amygdala (BLA), central nucleus of 
amygdala (CeA) and intercalated (ITC) cells of amygdala (modified from Maren et al., 2013). Black arrows 
represent glutamatergic excitatory projections, and the blunt line represents the GABAergic inhibitory 
projection.  The hippocampus projects directly to BLA, and this projection may be crucial for the renewal of 
fear expression in response to an extinguished conditional stimulus. The red arrows represent whether the 
context-dependent fear renewal is stimulated or suppressed in response to an extinguished conditional 
stimulus as a result of GABAergic CeA output neuron activation or inhibition.  
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2.2.4  Neuroanatomy of unconditioned (innate) fear 
Responses to predators and to aggressive conspecifics are processed via independent neural 
pathways that include different subnuclei of amygdala, hypothalamus and periaqueductal gray 
(PAG) (Figure 6). The interconnected anterior hypothalamic nucleus (AHN), the dorsomedial part 
of ventromedial hypothalamic nucleus (dmVMH), and ventrolateral part of dorsal premammillary 
nucleus (vlPMD) form a so-called medial hypothalamic defensive circuit (Canteras, 2002) that is 
also called a predator-responsive circuit (Gross and Canteras, 2012). Lesions in PMD have been 
effective in reducing antipredator defensive responses (Canteras et al. 1997; Blanchard et al. 2003). 
The medial hypothalamic defensive system receives neurochemical signals from the posteroventral 
part of medial amygdala (pvMEA) upon olfactory stimulus representing a predator and from LA 
and the posterior part of basomedial amygdala (pBMA) upon auditory/visual stimulus representing 
a predator (Gross and Canteras, 2012).  The vlPMD is the output nucleus of the predator-responsive 
circuit and it projects to the dorsolateral part of periaqueductal gray (dlPAG) (Gross and Canteras, 
2012). Fear response to aggressive conspecifics involves the posterodorsal part of medial amygdala 
(pdMEA), the ventrolateral part of ventromedial hypothalamus (vlVMH) and its connections with 
the medial preoptic nucleus (MPN) and ventral premammilliary nucleus (PMV), the dorsomedial 
part of dorsal premammillary nucleus (dmPMD) and the dorsomedial part of periaqueductal grey 
(dmPAG) (Gross and Canteras, 2012). 
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Figure 6. The fear response to an olfactory or auditory/visual stimulus representing a predator is mediated 
by a neural pathway that involves the posteroventral part of medial amygdala (pvMEA) or the lateral 
amygdala (LA) and the posterior part of basomedial amygdala (pBMA), respectively. Both pvMEA and 
pBMA project to the dorsomedial part of ventromedial hypothalamus (dmVMH) that is connected to the 
ventrolateral part of dorsal premammillary nucleus (vlPMD) both directly and indirectly via the anterior 
hypothalamic nucleus (AHN). The vlPMD projects to the dorsolateral part of periaqueductal grey (dlPAG). 
The fear response to aggressive conspecifics involves a pathway including the posterodorsal part of medial 
amygdala (pdMEA), the ventrolateral part of ventromedial hypothalamus (vlVMH) and its connections with 
the medial preoptic nucleus (MPN) and ventral premammilliary nucleus (PMV), the dorsomedial part of 
dorsal premammillary nucleus (dmPMD) and the dorsomedial part of periaqueductal grey (dmPAG). 
Dashed arrows indicate stimulus input and behavioral output (modified from Gross and Canteras, 2012). 
Also BNST and BLA are likely to play a role in unconditioned fear responses to predators, as 
lesions in both structures have exhibited a significant reduction in unconditioned fear responses to a 
predator odor (Fendt et al., 2003; Li et al., 2004; Rosen, 2004; Vazdarjanova et al., 2001). However, 
lesions in CeA have not been shown to affect the natural defensive responses to a predator (de Oca 
and Fanselow 2004) or to its odor (Li et al. 2004). Exposure of mice to 2,5-dihydro-2,4,5-
trimethylthiazoline, a synthetically derived component of fox feces, induced neuronal activation of 
the BNST, lateral septum (LS), paraventricular nucleus of hypothalamus, LC and PAG (Janitzky et 
al., 2015). Of these areas at least BNST and LS in addition to PAG receive direct innervations from 
the medial hypothalamic defensive system (Canteras, 2002). 
As shown by increased c-Fos expression, the elevated plus-maze-induced anxiety has been shown 
to activate  e.g. mPFC,  nuclei of amygdala (the medial, cortical and lateral nucleus of amygdala, 
BLA, and to a low extent also CeA) and  the crescentic LS, and it  has  been hypothesized  that  
they  are components  of  basic  neural  circuits  related  to  the  experience  of  anxiety  or  distress 
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(Duncan et al., 1996). Open-field exposure induced an increased c-Fos expression in the mPFC, 
cingulate, motor, somatosensory, insular, piriform and entorhinal cortices, LS, paraventricular 
thalamic nucleus, hypothalamus (anterior and lateral hypothalamic areas), amygdala (BLA, MEA), 
extended amygdala (BNST), hippocampus (CA1, subiculum) and LC (Hale et al., 2008). A local 
administration of a benzodiazepine site agonist midazolam into BLA showed an anxiolytic-like 
action by impairing the open arm avoidance in the plus-maze (Pesold and Treit, 1994, 1995). 
However, GABAergic drug action in the CeA did not have a similar effect as in the BLA because in 
the same protocol midazolam administration into CeA had no effect on the open arm activity in the 
plus-maze. A brightly lit test chamber has been shown to generate similar unconditioned fear in 
control animals and in animals with lesions in the CeA (Rosen, 2004). 
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3 Aims of the study  
Expanding the understanding of local role of GABAA receptors and neuronal circuits mediating 
anxiolysis is relevant for the development of more selective and safe treatment for anxiety 
disorders. Studying the properties of extrasynaptic GABAA receptors may help to understand their 
physiological relevance and role in psychiatric and neurological disorders. 
The main objectives of this thesis were as follows: 
 
1. To investigate whether benzodiazepine-sensitive GABAA receptors are expressed in human 
LC neurons. 
 
2. To study the pharmacology of extrasynaptic GABAA receptors in vivo in mice and in vitro 
in brain sections and recombinant receptors. 
 
3. To study the neuronal networks mediating acute anxiolytic responses. 
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4 Materials and methods 
4.1 Human brains (I) 
Postmortem brain tissue was obtained from the Section on Neuropathology of the Clinical Brain 
Disorders Branch, Genes Cognition and Psychosis Program of the Intramural Research Program of 
the National Institute of Mental Health under a protocol approved by the Institutional Review Board 
(IRB).  
The collection, screening, and analysis of subjects (2 females, 3 males, average age 30 ± 12.6 years) 
have been described in Lipska et al. (2006).  The cause of death was determined and the toxicology 
profile was defined from brain or blood samples. The interval between death and tissue collection 
ranged from 16 to 50.5 h. The pons and cerebellar cortex were cut into 2–3 cm thick slabs, flash 
frozen in dry ice and isopentane, and stored at -80 °C. 14-μm-thick sections were cut from the slabs 
of pons and cerebellar cortex with a Leica CM 3050S cryostat (Leica Microsystems, Benheim, 
Germany) at -20 °C. The sections were thaw-mounted onto gelatin-coated or SuperFrost object 
classes (Menzel-Gläser) and stored frozen at -70 °C. 
4.2 Experimental animals (II, III) 
All animal experiments were approved by the Southern Finland Provincial Government and the 
Institutional Animal Use and Care committee of the University of Helsinki. 
The Thy1?6 mice had been generated by microinjecting a transgene consisting of the Thy-1.2 pan-
neuronal promoter, the mouse GABAA receptor α6 subunit cDNA and the Thy1 polyadenylation 
site into the genome of two-cell embryos of CBA/cba x C57BL/6 (Caroni, 1997; Wisden et al. 
2002). The Thy1α6 founder line was expanded in C57BL/6 background for at least 10 generations 
(William Wisden, personal communication).  
The experimental Thy1α6 mice were produced in the animal facilities of the Korpi research group 
by mating within a homozygous line (II, III). The control C57BL/6NHsd mice (Harlan Netherland, 
Horst, The Netherlands) were purchased at the age of 5 weeks (II, III).  
To generate littermate wild-type controls for homozygous or heterozygous Thy1α6 mice (II), 
homozygous Thy1α6 mice were first mated with C57BL/6HNsd mice to produce heterozygous 
offspring. These heterozygous mice were then mated. Genotyping of the pups was performed from 
tail-tip samples by PCR (denaturing at 94°C for 3 min followed by 20 cycles, 94°C 30 s, 60°C 30 s, 
and 72°C 30 s) with primers (forward 5′-TCTTGCTTCTCCCCTGGCTCTTCA-3′ and reverse 5′-
45 
 
AGACGGTTGTCATAGCCTTCCAGC-3′) designed to discriminate between the endogenous 
Gabra6 gene (362 bp) and the transgenic intronless Gabra6 cDNA (160 bp). The presence of the 
shorter PCR product was used to identify the transgenic, either homozygous or heterozygous, mice. 
All experimental mice (II, III) were maintained until the experiments at the age of 3–6 months in 
groups of 2–6 in Makrolon cages (37 · 21 · 15 cm; Tecniplast, Buguggiate, Italy), under 12 : 12 h 
light : dark cycles (lights on 7 AM–7 PM), at 21–23°C and humidity of 50–60%. They received 
standard rodent pellets (Harlan BV., Horst, The Netherlands) and tap water ad libitum.  
For behavioral tests (II), the mice were transferred to the experimental room at least 1 h before drug 
injections, which were performed 30 min before behavioral tests. In the light : dark exploration and 
elevated plus-maze tests, the mice received an i.p. injection of either saline or gaboxadol 
hydrochloride (3 mg/kg; H. Lundbeck A/S, Copenhagen, Denmark). In the loss of righting reflex 
(LORR) test, 25 mg/kg gaboxadol hydrochloride was injected. 
For the immunohistochemical and autoradiography assays (III), the mice were pre-handled and 
accustomed to the test room and to injections for a week. On the test day, the mice were allowed to 
adapt to the test room at least 1 h before saline or gaboxadol (3 mg/kg, i.p.) injections. Immediately 
after the injections, the mice were returned in their home cages. Brain dissections were performed 
between 9 am and 1 pm, 2 h after the injections and the brains were frozen on dry ice and stored at  
-80 °C. 14-μm-thick coronal sections were cut with a cryostat (Leica CM 3050; Leica Microsystem, 
Nussloch, Germany), thaw-mounted onto gelatin-coated or SuperFrost object classes (Menzel 
Gläser) and stored frozen at -80 °C until used in the experiments. The mice were treated blindly for 
genotype and drug treatment. 
4.3 Behavioral tests (II) 
The light : dark exploration and elevated plus-maze tests have been described in Vekovischeva et al. 
(2004). All behavioral tests were performed between 9 AM and 1 PM. 
4.3.1  The light : dark exploration test  
A mouse was placed in the lit compartment of a two-compartment box (47 × 29 × 35 cm) divided 
into one dark (16 × 29 cm) and one lit (31 × 29 cm; about 450 lux) area separated by an open door 
(7 × 8 cm). During a 5-min testing period the time before the first crossing to the dark compartment 
(latency to the first entry), the number of crossings between the compartments and the time spent in 
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the lit compartment (minus the latency) were recorded and analyzed by EthoVision Color-Pro 3.0 
software (Noldus Information Technology, Wageningen, The Netherlands). 
4.3.2  The elevated plus-maze test  
A mouse was placed on the central platform facing the open arm and was allowed a free exploration 
of the maze for 5 min. The time spent on the open arms, number of entries into the open and closed 
arms, and total movements were recorded and analyzed using the EthoVision video tracking 
system. The elevated plus-maze apparatus (gray plastic; elevated 54 cm from the floor level) 
consisted of a central platform (5 × 5 cm), from which two open arms (5 × 40 cm with a 0.7 cm 
marginal elevation) and two closed arms (5 × 40 × 20 cm) extended. The light intensity was set at 
50 lux on the open arms, and 20 lux in the closed arms.  
4.3.3  The LORR (loss of righting reflex) test  
The LORR was determined every 4 min by turning a mouse in a supine position consecutively for 3 
times on a V-shaped trough made of plastic. The mouse was considered to have lost its righting 
reflex when it was not able to right itself in any of three consecutive 5-s trials and gained the 
righting reflex when it was able to right itself at least once of the three trials. 
4.4 Immunohistochemistry (I, III) 
4.4.1 Tyrosine hydroxylase (TH) immunohistochemistry (I) 
A rapid staining procedure as described in the instructions of Vectastain Elite ABC Kit (Vector 
laboratories) was applied. The human brain sections on gelatin-coated object classes were fixed in 
cold acetone for 5 min and washed briefly in 1× phosphate-buffered saline (PBS), pH 7.4. The first 
incubation was performed in the 1:25 dilution of primary rabbit anti-TH affinity-purified polyclonal 
antibody (AB152; Chemicon International, Temecula, USA), the second in the 1:50 dilution of 
secondary biotinylated anti-rabbit goat IgG (PK-6105; Vectastain Elite ABC Kit, Vector 
laboratories) and the third in the avidin/biotinylatedhorseradish peroxidase enzyme complex ABC 
(Vectastain Elite ABC Kit, Vector laboratories), each at room temperature for 4 min and with a 
brief rinsing with 1× PBS between each step. After the color development with diaminobenzidine 
(DAB) (Vector laboratories) for 60 s, the sections were rinsed in H2O, and then dehydrated in 70%, 
95% and 100% ethanol (30 s each) and xylene (twice for 5 min each). Finally, glass cover slips 
(Menzel-Gläser) were mounted on the sections. Negative controls were carried out in the absence of 
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the primary antibody. The LC sections were scanned (Epson expression 1680 Pro) with digital 
manipulation (shadow 179, gamma 2.89, highlight 215). 
4.4.2  C-Fos immunohistochemistry (III) 
The staining procedure has been described in Procaccini et al. (2011). The frozen slides on 
SuperFrost object classes were air-dried for 15 min, surrounded with a hydrophobic pen (Daigo 
Sangyo, Tokyo, Japan) and fixed for 10 min in ice-cold 4% paraformaldehyde in PBS (pH 7.4). The 
slides were washed in PBS containing 0.05% Tween 20 (PBST20) and blocked for endogenous 
peroxidases in methanol containing 0.3% hydrogen peroxide for 15 min. After washing in PBST20, 
the slides were incubated for 20 min in a blocking buffer consisting of 5% horse normal serum and 
1% fatty acid free bovine serum albumin (BSA) in PBST20. After washing in PBST20, the goat 
polyclonal anti-c-Fos antibody (1:1000, SC-52G, Santa Cruz Biotechnology, Santa Cruz, CA) was 
applied in the incubation buffer (1% BSA in PBST20) overnight at 4 °C. Negative control sections 
were incubated without the primary antibody. On the next day, slides were washed with PBST20 
and incubated in a solution containing biotinylated horse anti-goat IgG (1:200; Vector Laboratories, 
Burlingame, CA) in 1% BSA in PBST20 for 1 h followed by an incubation in an avidin-horseradish 
peroxidase solution for 1 h (Vectastain Elite ABC, Vector). After washing in PBST20, the sections 
were incubated in a chromogen solution containing diaminobenzidine and nickel sulfate 
intensification (DAB Substrate kit, Vector) for 8 min. The reaction was stopped by PBST20. The 
sections were dehydrated in ethanol series, immersed in Histoclear (National Diagnostic, Atlanta, 
GA, USA) and coverslipped with Permount (Fisher Chemicals, Fair Lawn, NJ). 
Photomicrographs from anatomically matched sections were captured blind to the treatment, 
genotype and sex using a light microscope (Leica DMR, Leica Microsystems, Wetzlar, Germany) 
and a CCD camera (Leica DC 300). Image Pro Plus digitizing software (Media Cybernetics, Silver 
Spring, ML) was used to set thresholds and to count c-Fos positive cells.  
4.5 In situ hybridization (I, III) 
The in situ hybridization procedures followed the protocol as described earlier by Sinkkonen et al. 
(2004). The air-dried sections on SuperFrost object classes (Menzel-Gläser) were fixed in ice-cold 
4% paraformaldehyde for 5 min, washed in 1× PBS at room temperature for 5 min, dehydrated in 
70% ethanol for 5 min and stored in 95% ethanol at 4 °C until used (I, III).  
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Two different antisense DNA oligonucleotide probes complementary to the human γ2 subunit 
mRNA sequence (nucleotides 1442–1486 and 1695–1739; GenBank accession 
number NM_198904) and analogous sense probes (I) as well as one antisense DNA oligonucleotide 
probe complementary to the mouse GABAA receptor α6 subunit mRNA sequence (5’-CAG TCT 
CTC ATC AGT CCA AGT CAT-3’) (III) were synthesized (Oligomer Oy, Helsinki, Finland). 
Poly[35S]dA ([35S]dATP from PerkinElmer Life and Analytical Sciences, Boston, MA, USA) tails 
were added to the 3′-ends of the probes by deoxynucleotidyl transferase (Promega Corporation, 
Madison, WI, USA) and unincorporated nucleotides were removed by Illustra ProbeQuant G-50 
Micro Columns (Amersham Biosciences, Buckinghamshire, UK). Sufficient labelling efficiencies 
were confirmed by a scintillation counter (I, III).  
The labelled probes were diluted to 0.06 fmol/μl with hybridization buffer (containing 50% 
formamide, 10% dextransulphate, 4× SSC) (I, III). Non-specific controls contained a 100-fold 
excess of unlabelled antisense probes. The hybridization occurred under glass cover slips (Menzel-
Gläser) over-night at 42 °C. The next day, the slides were washed in 1× SSC at room temperature 
for 10 min, in 1× SSC at 55 °C for 30 min, and 1× SSC, 0.1× SSC, 70% EtOH and 95% EtOH at 
room temperature for 1 min each. After air-drying, the sections were exposed with plastic 14C-
radioactivity standards (GE Healthcare, Little Chalfont, Buckinghamshire, UK) to BioMax MR film 
(Eastman Kodak Company, Rochester, NY, USA) for up to a week and scanned for images (Epson 
expression 1680 Pro). The binding densities were measured as optical density values (SCION 
IMAGE; Wayne Rasband, NIMH, Bethesda, MD) and converted to radioactivity levels in nCi/g of 
gray matter for [35S]-labelled oligonucleotides. Non-specific signal was subtracted to obtain the 
specific signal. 
For emulsion autoradiography (I), the sections were dipped in Kodak autoradiography emulsion 
(Eastman Kodak Company, Rochester, NY, USA) diluted in 600 mM ammonium acetate (1:1 
volume) in the 42 °C water bath, air-dried over-night in the dark and exposed in a light-tight slide 
box at 4 °C for 6 weeks. The sections were developed at 15 °C in Kodak D-19 Developer for 3 min, 
water for 30 s, and Kodak fixer for 5 min, after that they were washed twice in water for 5 min and 
air-dried over-night at room temperature. The dry sections were counterstained by 0.125% thionin, 
rinsed in water, dehydrated in ethanol series (70%, 95%, 100%) and xylene and mounted by cover 
slips. Conventional transmitted and darkfield images were acquired using Olympus AX70 
microscope with UPlanF1 20×/0.50 NA or PlanApo 60×/1.40 NA Oil objectives. 
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4.6 Autoradiographic binding assays (I, II, III) 
4.6.1  The [3H]Ro 15-4513 autoradiography (I, III) 
The [3H]Ro 15-4513 autoradiographic binding assays were modified from Mäkelä et al. (1997). 
Brain sections on gelatin-coated object classes were pre-incubated in ice-cold 50 mM Tris–HCl 
buffer, pH 7.4, containing 120 mM NaCl for 15 min. The final incubation was performed in the pre-
incubation buffer containing 15 nM [3H]Ro 15-4513 (PerkinElmer Life and Analytical Sciences, 
Boston, MA, USA) without (basal binding) or with 1 nM to 10 μM zolpidem or 10 μM flumazenil 
(non-specific binding) for human brain sections (I) and without (basal binding) or with 10 μM 
diazepam or 10 μM flumazenil (non-specific binding) for brain sections of saline or gaboxadol-
injected Thy1α6 or C57BL/6NHsd mice (III) at 4 °C for 1 h. The sections were washed in ice-cold 
pre-incubation buffer twice for 1 min, dipped in ice-cold distilled water, air-dried at room 
temperature and exposed with 3H-plastic standards (GE Healthcare, Little Chalfont, 
Buckinghamshire, UK) to BAS-TR 2040 imaging plate (Fujifilm Corp., Tokyo, Japan) for up to 2–
3 days (I) or to Biomax MR films (Eastman Kodak, Rochester, NY, USA) (III).  
The binding densities were measured as optical density values (SCION IMAGE; Wayne Rasband, 
NIMH, Bethesda, MD) from digitalized images scanned by the FLA-9000 Starion image scanner 
(Fujifilm) (I) or by Epson expression 1680 Pro scanner (III) and converted by co-exposed 3H-
standards to nCi/mg for [3H]Ro 15-4513 binding.  
4.6.2  The [35S]TBPS autoradiography (II, III) 
The [35S]TBPS autoradiographic binding assay has been described in Sinkkonen et al. (2001). 14-
μm-thick horizontal brain sections on gelatin-coated object glasses were pre-incubated in ice-cold 
buffer containing 50 mmol/L Tris–HCl (pH 7.4) and 120 mmol/L NaCl for 15 min. The final 
incubation was performed at 22 °C for 90 min in the buffer containing 6 nmol/L [35S]TBPS (Perkin-
Elmer, Boston, MA, USA) without (basal binding) or with 1 mmol/L gaboxadol hydrochloride and 
10 mmol/L GABA (Sigma, St Louis, MO, USA), 1 μmol/L – 10 mmol/L GABA, 1 mmol/L 
gaboxadol hydrochloride (Sigma) or 100 μmol/L picrotoxin (Sigma) (non-specific binding) for 
naive adult Thy1α6 and control C57BL/6NHsd mouse brain sections (II) and in the buffer 
containing 2 nmol/L [35S]TBPS without (basal binding) or with 10 mM GABA, 1 mM gaboxadol 
hydrochloride, combination of 1 mM gaboxadol hydrochloride and 10 mM GABA, combination of 
10 mM GABA and 100 μM furosemide (Sigma) or 100 μM picrotoxinin (non-specific binding) for 
brain sections of saline or gaboxadol-injected Thy1α6 or C57BL/6NHsd mice (III). After 
incubations, the sections were washed 3× 30 min in ice-cold 10 mmol/L Tris–HCl (pH 7.4), dipped 
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into distilled H2O, air-dried at 22 °C, and exposed with plastic 14C radioactivity standards (GE 
Healthcare, Little Chalfont, Buckinghamshire, UK) to Biomax MR films (Eastman Kodak, 
Rochester, NY, USA) for up to 6 weeks (II, III).  
The binding densities were quantified on films by MCID M5 image analysis devices and programs 
(Imaging Research Inc., St. Catharines, ON, Canada) (II) or on scanned films by SCION IMAGE 
(III), and by using the simultaneously exposed 14C-standards as the reference, the binding values 
were converted to radioactivity levels estimated for gray matter areas (nCi/g) for [35S]TBPS 
binding.  
4.7 Cell culture and transfection (II) 
Human embryonic kidney cell line (HEK293) were passaged and replated on 12-mm glass 
coverslips located in 9.6-cm plastic dishes filled with 10 mL of Minimum Essential Medium 
supplemented with 158 mg/L sodium bicarbonate, 2 mmol/L glutamine, 100 U/mL penicillin–
streptomycin, and 10% fetal calf serum (all from Invitrogen, Karlsruhe, Germany). Cultures were 
maintained at 37 °C in a humidified 95% O2/5% CO2 atmosphere for 2–3 days. 
Transfections were carried out as described in Korpi and Lüddens (1993) and Lüddens and Korpi 
(1997) in double or triple subunit combinations using the phosphate precipitation method with rat 
GABAA receptor cDNAs in eukaryotic expression vectors. To identify transfected cells all subunit 
combinations except δ-internal ribosome entry site- enhanced green fluorescent protein (EGFP) 
were co-transfected with 1 μg of pN1-EGFP per plate. 
4.8 Electrophysiology (II) 
Two days after transfection single coverslips with human embryonic kidney cell line (HEK293) 
were placed in a recording chamber mounted on the movable stage of a fluorescence microscope 
(Olympus IX70; Olympus Optical CO. Europa GmbH, Hamburg, Germany) and perfused with a 
recording solution at 22°C. Transfected cells were identified by their eGFP fluorescence. Ligand-
mediated membrane currents in these cells were studied in the whole-cell configuration of the 
patch-clamp technique (Rabe et al. 2007).  
Dose-responses of GABA and gaboxadol and the kinetics of GABA and gaboxadol-induced peak 
currents were studied on HEK293 cells expressing α6β3, α6β3δ, α6β3γ2, or α4β3δ receptors. 0.01–
1000 μmol/L of gaboxadol hydrochloride or GABA was applied to the cells with a fast application 
system (SF-77B, Perfusion Fast Step; Warner Instruments, LLC, Hamden, CT, USA). The binding 
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site competition by GABA and gaboxadol was tested on HEK cells expressing α6β3δ and α6β3γ2 
receptors. 1 mmol/L GABA or gaboxadol or 1 mmol/L GABA or gaboxadol and 0.1, 1, 10, 100, 
and 1000 μmol/L gaboxadol or GABA, respectively, were applied to the cells.  
Cell responses were recorded by a patch-clamp amplifier (EPC-8; HEKA-Electronic, Lambrecht, 
Germany) in conjunction with a standard computer and the pClamp 8.1 software package (Axon 
Instruments, Foster City, CA, USA). Data analysis was performed using the appropriate programs. 
4.9 Statistical analyses (II, III) 
Statistical analyses of the data were carried out using two- and three-way ANOVAs, non-parametric 
Mann–Whitney test,  Wilcoxon matched pairs, Student’s t-test, two-tailed Welch t-test and 
Newman-Keuls comparisons with the statistical software packages SPSS 10.0.7 or 14.0.1 for 
Windows (SPSS, Chicago, IL, USA) and the PRISM 3.0 or 5.0 program (GraphPad Software, San 
Diego, CA, USA). 
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5 Results and discussion 
5.1 Human LC neurons express GABAA receptor γ2 subunit mRNA and 
benzodiazepine binding sites (I) 
The current study was performed in order to investigate whether the human LC neurons express the 
GABAA receptor γ2 subunit mRNA and benzodiazepine binding sites. Benzodiazepines are well 
known anxiolytics, and could in theory directly decrease anxiety and the associated arousal and/or 
insomnia by increasing the activity of the γ2 subunit-containing GABAA receptors on the LC 
neurons thereby decreasing the firing of these cells. However, contradictory reports had been 
published in regard to the expression and participation of the γ2 subunit in the functional GABAA 
receptors in the mammalian LC. Some studies had suggested the presence of γ2 subunit mRNA or 
protein in the rat LC (Fritschy et al., 1992; Lüddens et al., 1995; Caldji et al., 1998 and 2000), 
whereas many studies could not detect the γ2 subunit gene expression in the rodent LC (Araki et al., 
1992; Luque et al., 1994; Tohyama and Oyamada, 1994). Based on pharmacological investigations, 
Chen and colleagues (1999) concluded that the GABAA receptors of the rat LC neurons do not 
contain the γ subunit. 
The localization of the LC in the human pons sections was determined by TH 
immunohistochemistry and by the endogenous neuromelanin pigment that gives the natural bluish-
grey color for the LC. Neuromelanin is a waste product of catecholamine metabolism, derived from 
the oxidation of catecholamines and related compounds to quinones (German et al., 1988). 
Noradrenaline is synthesized from tyrosine (tyrosine → dopa → dopamine → noradrenaline), and 
the rate-limiting enzyme in this process is TH which can be used to label the noradrenergic neurons 
in the LC. However, although most TH expressing neurons in the human LC contain neuromelanin 
pigment, some larger neurons lack the pigmentation (Chan-Palay and Asan, 1989).  
In this study, a clear γ2 mRNA signal was revealed in the human LC. The finding is reliable as 
consistent results were obtained by two antisense probes designed to hybridize to different locations 
of the human GABAA receptor γ2 subunit mRNA. The emulsion autoradiography, that gives 
information with a cellular level resolution, revealed that the γ2 subunit mRNA was expressed over 
the entire LC, including neuronal somas within the structure, covering both neuromelanin-
pigmented and non-pigmented somas. In the negative control experiments with complementary 
sense probes and with competition hybridizations with an excess of unlabelled antisense probes 
only a very weak signal was detected on the films. The signal was completely absent in the negative 
controls after the emulsion autoradiography indicating that the faint signal on the film was an 
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artefact. The cerebellar granule cell layer served as a positive control for the γ2 subunit mRNA 
expression, and a strong expression was detected there, thus further increasing the reliability of the 
study. 
As a clear γ2 subunit mRNA expression was detected in the human LC, it was further investigated 
whether the subunit is assembled in GABAA receptors within the structure. As Ro 15-4513 exhibits 
high affinity to all GABAA receptors consisting of αβγ subunit combinations (Sieghart, 1995), a 
[3H]Ro 15-4513 binding autoradiography was performed. The [3H]Ro 15-4513 binding was clearly 
detected in the LC and in the cerebellar granule cell layer that was used as a positive control for 
benzodiazepine binding (Albin and Gilman, 1990). The benzodiazepine binding-site antagonist 
flumazenil displaced all [3H]Ro 15-4513 binding in the sections. These results indicate that the γ2 
subunit is assembled in GABAA receptors in the human LC.  
To further investigate the subunit combination in the benzodiazepine-binding receptors, we tested 
whether there were binding sites for zolpidem, an α1 subunit-preferring benzodiazepine-site agonist 
that has little or no sensitivity to γ1/γ3 subunit-containing receptors (Lüddens et al., 1994; Sanna et 
al., 2002). The cerebellar granule cell layer was used as a positive control as it expresses α1 
subunits but not α2/3 subunits in rats (Wisden et al., 1992). Based on the IC50 values for zolpidem 
determined by displacement of [3H]Ro 15-4513 binding, our results indicate that the  GABAA 
receptors in the human cerebellar granule cell layer are 3-times more sensitive to zolpidem than 
those in the LC, but as zolpidem displays about 10-fold higher affinity to α1 subunit-containing 
receptors than to α2/3 subunit-containing receptors (Hadingham et al., 1993), it is likely that the α1 
as well as α2/3 subunits are assembled in the GABAA receptors in the human LC. However, it 
cannot be fully excluded that the α2/3 subunits would be expressed in the human cerebellar granule 
cell layer and that the sensitivity difference between the granule cells and LC would have been due 
to some α1 expression in granule cells and none in LC. It is however most likely that also the α1 
subunits assemble in receptors in the human LC as Waldvogel and colleagues (2010) reported α1 
immunoreactivity in the human LC. In that study, the neuromelanin-pigmented neurons of LC were 
highly immunopositive for the GABAA receptor α3 and γ2 subunits and minimally labeled by α1, 
α2, or β2/3 subunit-antibodies. The non-pigmented neurons interspersed between the pigmented 
neurons and were immunopositive for the α1 and β2/3 subunits. The autoradiography films do not 
allow a cellular level analysis, and therefore it cannot be determined whether the α1 and α2/3 
subunits in our LC samples were located in pigmented or non-pigmented neurons. In mice, the 
GABAA receptor α1 and α2 subunits have been associated with sedative and anxiolytic effects of 
benzodiazepines, respectively (McKernan et al., 2000; Löw et al., 2000). In the current study it was 
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shown that the γ2 subunit is expressed in the neuromelanin-pigmented and non-pigmented human 
LC neurons and that the LC neurons express α1, α2/α3 and γ2 subunit-containing GABAA receptors 
likely in the same neurons that express the γ2 mRNA. These findings indicate that the human LC 
may directly mediate the sedative and/or anxiolytic effects of benzodiazepines. This study does not 
provide an answer to the inconsistent findings related to the γ2 subunit expression in the rodent LC, 
but there is a possibility that there is a species difference in the expression profile of the γ2 subunit 
in the LC. If the benzodiazepine binding sites are more abundant in the LC of man than rodents, the 
anxiolytic drugs in rodents may produce pronounced adverse sedative effects in man via the γ2 
subunit-containing benzodiazepine binding sites in the LC. However, any of the α1, α2 or α3 
subunits may assemble in human LC with the γ2, and one of the reasons for the association of the 
mouse α1 subunit with the sedative effects of benzodiazepines may result from benzodiazepine 
action in other brain regions than LC. 
5.2 The Thy1α6 mouse model expresses ectopically the GABAA receptor α6 
subunit contributing to extrasynaptic receptors and tonic inhibition 
The transgenic Thy1α6 mice express the GABAA receptor α6 subunit gene under the Thy-1.2 
promoter, and the first study on the mouse line reported an ectopic mRNA expression of GABAA 
receptor α6 subunit in many brain regions including deep cerebellar nuclei, deep layers of 
neocortex, layer II of neocortex in the somatosensory area, hippocampal pyramidal cells and dentate 
granule cells, cells in the septum and olfactory bulb mitral cells (Wisden et al., 2002). Of the 
investigated Thy1α6 mouse brain areas, only some cells were α6-immunopositive and most often 
large cell types displayed strong α6 immunoreactivity. Strong α6 subunit immunoreactivity was 
reported in the globus pallidus, zona reticulata of the substantia nigra, nucleus ruber, large cells in 
the intermediate gray layer of superior colliculus, some cells of the pontine nuclei, the vestibular 
nuclei, deep cerebellar nuclei, gigantocellular reticular formation, trigeminal nucleus and lateral 
reticular nucleus. In α6 immunopositive cells, the transgene was always present in the cell body, 
and the dendrites were α6 immunopositive to different extent in different neurons (Wisden et al., 
2002).   
It was reported that in the Thy1α6 mouse forebrain, the α6 subunit-containing receptors contained 
also the γ2 subunit or consisted of α6β receptors (Wisden et al., 2002; Sinkkonen et al., 2004), and 
that the α6 subunit-containing receptors were largely located extrasynaptically in the pyramidal 
cells of CA1 hippocampal area, a brain area that was chosen for more detailed microscopic 
investigation due to a strong α6 subunit protein expression on the entire somato-dendritic surface of 
55 
 
the neurons (Wisden et al., 2002).  As compared to control C57BL/6 mice, the CA1 pyramidal 
neurons of the Thy1α6 mice had a five-fold increased tonic GABAA receptor-mediated current 
(Wisden et al., 2002), further supporting the extrasynaptic nature of the receptors containing the 
ectopically expressed subunit. This is also in line with the finding that in its natural environment in 
cerebellar granule cells, the α6 subunit forms extrasynaptic receptors with β2/3 and δ subunits 
(Barnard et al., 1998). In cerebellar granule cells, the α6 subunit assembles also in receptors 
containing the γ2 subunit. The majority of the α6βγ2 receptors are located synaptically, although 
some of these receptors have also been detected in the extrasynaptic membrane in cerebellar granule 
cells (Nusser et al., 1998).   
5.3 Earlier behavioral characterization of consequences of ectopic expression of 
GABAA receptor α6 subunits 
Thy1α6 mice are healthy, grow and breed as the control C57BL/6 mice. The initially performed 
basic characterization of their phenotype according to a standardized set of experimental procedures 
revealed no strain differences in most of the studied parameters (Sinkkonen et al., 2004). Only the 
tests on startle reflex and struggle-escape behavior showed that the Thy1α6 mice were more 
sensitive to the acoustic stimuli and had an enhanced struggle-escape behavior as compared to the 
control C57BL/6 mice. Therefore, a slightly increased behavioral excitability of the Thy1α6 mice 
was suggested by the authors, even though no changes in anxiety, exploration or working memory 
of the Thy1α6 mice were observed in the in the light–dark or T-maze test (Sinkkonen et al., 2004).   
The first behavioral consequence of the increased tonic conductance in the Thy1α6 mice was 
observed when a low dose of a GABA uptake blocker, the antiepileptic drug tiagabine (i.p., 30 min 
prior to i.p. picrotoxinin) delayed the picrotoxinin-induced generalized tonic-clonic convulsions in 
the Thy1α6 mice as compared to the wild-type C57BL/6 controls. However, higher tiagabine 
concentrations had a stronger antiepileptic effect in the control mice (Sinkkonen et al., 2004).  
5.4 The Thy1α6 mice display an enhanced sensitivity to anxiolytic-like and 
sedative effects of gaboxadol (II) 
In order to investigate further the behavioral consequences of the enriched extrasynaptic GABAA 
receptors, they were aimed to be selectively activated by gaboxadol in the present study. It had been 
shown in recombinant GABAA receptors that gaboxadol had higher potency and relative efficacy 
(as compared to GABA) in α6β3δ, 4β3δ and α4β3 receptors as compared to α1-6β3γ2 receptors of 
which the α2/5/6β3γ2 receptors displayed the highest sensitivity to gaboxadol and the efficacy of 
56 
 
GABA and gaboxadol were similar in these receptors. The α1/3/4β3γ2 had the lowest sensitivity to 
gaboxadol that was a partial agonist in them as compared to GABA (Ebert et al., 2001; Storustovu 
and Ebert, 2006). The α4βδ GABAA receptors have been reported to locate extrasynaptically 
mediating tonic conductance in thalamus (Cope et al., 2005; Jia et al., 2005; Richardson et al., 
2013). In line with these findings, suggesting that gaboxadol acts preferentially via extrasynaptic 
α6β3δ, α4β3δ and α4β3 receptors, we expected that especially the extrasynaptic α6β receptors (but 
also α6βγ2 receptors) would be more sensitive to gaboxadol than the typical synaptically located 
GABAA receptors, and that this enhanced sensitivity would become visible in the behavior of the 
transgenic mice ectopically expressing the α6 subunit. 
Indeed, gaboxadol induced strong anxiolytic-like response in the light : dark exploration and 
elevated plus-maze tests in Thy1α6 mice at 3 mg/kg, while the anxiolytic behavior was largely 
unaffected in the gaboxadol-treated wild-type C57BL/6 NHsd mice. In the light : dark exploration 
test, this anxiolytic-like behavior of the transgenic mice was shown as a shortened latency to the 
first dark entry, an increased number of crossings between the compartments, and in a doubled time 
the mice spent in the lit compartment. There was no difference between saline-treated 
C57BL/6NHsd control and Thy1α6 mice, except that there was a significant delay in the first entry 
into the dark compartment in the transgenic mice. In the elevated plus-maze test, gaboxadol was 
notably more effective in increasing the time on the open arms in the Thy1α6 mice than in the 
C57BL/6 NHsd mice, whereas the saline-treated mouse lines did not differ in any of the tested 
parameters. Neither test showed any sedative effect at this low dose of gaboxadol in either mouse 
line as determined by measuring crossings and total movements. The gaboxadol-treated female 
Thy1α6 mice had slightly, but significantly more crossings than the gaboxadol-treated Thy1α6 
males, C57BL/6 NHsd males or C57BL/6NHsd females in the light : dark exploration test. In the 
elevated plus-maze test the saline-treated control males moved significantly more than the saline-
treated females, the Thy1α6 males or females. However, there were no significant gender effects on 
the time in lit area or on time on open arms.  
Differences in early nursing or genetic background could have had a role in the sensitivity 
difference between the Thy1α6 and C57BL/6NHsd mice to gaboxadol. The transgenic mice had 
been generated by injecting the Thy1α6 transgene into mouse eggs (strain CBA/cba×C57BL/6), and 
the Thy1α6 founder line was repeatedly expanded in C57BL/6 background for at least 10 
generations. In the current study, the experimental Thy1α6 mice were produced by mating within a 
homozygous line, and the control C57BL/6NHsd mice were purchased at the age of 5 weeks. 
Thereafter, the mice were maintained until the experiments at the age of 3–6 months. In order to test 
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the potential confounding effects of genetic background and early nursing on the result, the Thy1α6 
mice were backcrossed into C57BL/6HNsd mouse line to produce heterozygous offspring that were 
then mated to generate transgenic Thy1α6 mice (heterozygous and homozygous) and littermate 
wild-type controls. The behavioral difference after 3 mg/kg of gaboxadol was confirmed in these 
backcrossed transgenic and wild-type littermate mice. In the backcrossed Thy1α6 mice, gaboxadol 
increased significantly the time spent in the lit area and the number of crossings between the 
compartments in the light : dark exploration test. In general the latencies to the first dark entry were 
much shorter in the backcrossed mice than in the original Thy1α6 and C57BL/6HNsd control mice. 
The saline-treated backcrossed transgenic mice had a similar latency as the wild-type littermates 
deviating from the result obtained in the saline-treated original Thy1α6 and C57BL/6HNsd control 
mice. Even though gaboxadol prolonged the latency to the first dark entry of the wild-type 
littermates and had an opposite effect on the backcrossed Thy1α6 mice, the time in the lit area, i.e. 
the main indicator for the anxiolytic-like response, showed very similar results between the 
littermate and non-littermate transgenic and wild-type mice. Therefore, the initial differences in the 
latencies unlikely affected the observed anxiolytic-like response of the Thy1α6 mice to gaboxadol.  
The Thy1α6 mice were also more sensitive to gaboxadol-induced hypnosis as assessed by the 
latency to and the duration of the LORR after administration of gaboxadol hydrochloride (25 
mg/kg, i.p.).  As compared to the wild-type C57BL/6NHsd mice, the Thy1α6 mice lost quicker and 
for longer time their righting reflex after the gaboxadol treatment. Furthermore, three out of eight 
wild-type mice did not lose their righting reflex and they were excluded from the data.  
As gaboxadol did not induce any consistent effects on the locomotor activation, it is concluded that 
the response of transgenic mice to gaboxadol was anxiolytic-like rather than motor stimulant. 
GABAA receptor-mediated anxiolysis has been traditionally associated with α2βγ2 receptors based 
on studies with benzodiazepines (Löw et al., 2000), but in the Thy1α6 mice the strong anxiolytic 
response to gaboxadol was most likely mediated via the α6 subunit-containing GABAA receptors. 
Considering the enhanced behavioral sensitivity of the Thy1α6 mice to both anxiolytic and hypnotic 
effect of gaboxadol as compared to the wild-type mice, it seems likely that the α6 subunit-
containing receptors formed extrasynaptic receptors with enhanced pharmacological sensitivity to 
gaboxadol.   
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5.5 The enhanced behavioral sensitivity to gaboxadol is likely mediated via α6β3 
and α6β3γ2 GABAA receptors 
The α6β receptors are about four times more sensitive to gaboxadol than α6βγ2 receptors (see the 
later sections of results) suggesting that gaboxadol produces the anxiolytic-like responses in 
Thy1α6 mice by activating the ectopic α6β receptors. Pharmacokinetic studies on rats by Cremers 
and Ebert (2007) showed that subcutaneously injected gaboxadol entered rapidly the brain with 
peak CNS concentrations in the range of 0.7 to 3 μM after one dose of gaboxadol at 2.5, 5 and 10 
mg/kg. A very short half-life (28 min) of gaboxadol was observed in both plasma and CNS 
(Cremers and Ebert, 2007).  Assuming that similar pharmacokinetics of gaboxadol applies also to 
mice and fitting our data on recombinant receptors to the Hill equation (I = Imax/(1 +(EC50/ [C])n), 
where Imax is the maximal current density induced by 1 mmol/L gaboxadol, [C] is 1 μM (the 
estimated CNS concentration after one dose of gaboxadol at 3 mg/kg) and n is the apparent Hill 
coefficient (approximately equal to 1)) separately for α6β3γ2 and α6β3 receptors, the current 
densities (I) at 1 μM gaboxadol concentration in the brain are equivalent (9.2 pA/pF) via both 
α6β3γ2 and α6β3 receptors. In other words, based on this calculation, the sensitivity difference 
between these receptors to 1 μM gaboxadol is offset by the greater gaboxadol-induced current 
density in α6β3γ2 receptors than in α6β3 receptors. Therefore, it is likely that the anxiolytic dose of 
gaboxadol activates both the α6β3 and α6β3γ2 receptors in the Thy1α6 mice. When fitting our data 
on recombinant receptors into the Hill equation with [C] of 7.5 μM (the estimated CNS 
concentration after one hypnotic dose of gaboxadol at 25 mg/kg), the current density (I) is 44.9 and 
60.4 pA/pF via the α6β3 and α6β3γ2 receptors, respectively. This suggests that at such high 
gaboxadol concentration, the current density is higher via α6β3γ2 despite of the lower sensitivity. 
It is also unlikely that these pronounced behavioral effects of gaboxadol were mediated via any 
compensatory increase in the function of synaptic GABAA receptors in the transgenic mice. In 
Mortensen et al. (2010) the potencies and efficacies of gaboxadol were studied in recombinant 
α1β3γ2 and α4β3δ receptors. It was shown that in α4β3δ receptors, gaboxadol was more than twice 
as efficient as in α1β3γ2 receptors, but in addition to that, the α4β3δ receptors were eight times 
more sensitive to gaboxadol than the α1β3γ2 receptors. In the present study, α1β3γ2 receptors were 
not investigated but based on this information and our electrophysiological data, it can be assumed 
that the overexpressed extrasynaptic GABAA receptors selectively mediate the enhanced behavioral 
sensitivity of Thy1α6 mice to gaboxadol. According to Wafford and Ebert (2006), gaboxadol has no 
effect on synaptic currents at concentrations of up to 3 μM. In addition, the frequency of 
spontaneous inhibitory postsynaptic currents and amplitudes of mIPSCs were decreased in the CA1 
59 
 
pyramidal neurons of the Thy1α6 as compared to wild-type mice (Wisden et al., 2002), suggesting a 
reduced synaptic GABAA receptor function. However, the Thy1α6 mice were also less sensitive to 
electroshock-induced convulsions and had decreased amplitudes in the AMPA receptor-mediated 
miniature excitatory postsynaptic currents (mEPSCs) in patch clamp recordings of CA1 pyramidal 
neurons in hippocampal slices (Möykkynen et al., 2007). It is likely that this decrease in the 
postsynaptic excitability was a compensatory response to the reduction in the postsynaptic 
GABAergic inhibition, but it is not possible to fully exclude the possibility that in the transgenic 
mice the function of the postsynaptic excitatory AMPA receptor system would have been disabled 
more than the synaptic GABAA receptor system and therefore, or partly therefore, less gaboxadol 
would have been sufficient to induce the anxiolytic and hypnotic effects in the Thy1α6 mice. On the 
other hand, the non-treated Thy1α6 mice were more sensitive to the acoustic stimuli and had an 
enhanced struggle-escape behavior as compared to the control C57BL/6 mice (Sinkkonen et al., 
2004), suggesting that the function of the neuronal excitatory system is not decreased at least in 
regions mediating the acute fear responses.  
An enhanced behavioral sensitivity to ataxic, sedative, and analgesic effects of gaboxadol at 10 
mg/kg has been associated with the α4 subunits that are expressed at high levels in the dentate gyrus 
and thalamus and contribute to extrasynaptic GABAA receptor-mediated tonic inhibition (Chandra 
et al. 2006). Although the Thy1α6 mouse model is expressing the α6 subunit in neurons where it is 
normally absent, the model allows examining the function of the added α6 subunit-containing 
extrasynaptic GABAA receptors and it provides in vivo evidence that anxiolytic and hypnotic doses 
of gaboxadol act preferentially via α6 subunit-containing GABAA receptors. 
5.6 GABA-insensitive [35S]TBPS autoradiographic signal reflects partial agonism 
of GABA (II) 
TBPS blocks the of ion flux through the GABAA receptor by binding to the ionophore/convulsant 
site (Korpi et al., 2002a). Basal [35S]TBPS binding represents non-conducting GABAA receptors 
and dissociation of [35S]TBPS by agonists, serves as a biochemical measure of receptor activation 
(Im and Blakeman, 1991, Sinkkonen et al., 2001). It has been shown that the displacement of 
[35S]TBPS binding by saturating concentration of GABA partially fails in the cerebellar granule cell 
layer and thalamus in contrast to the majority of other brain regions (Sinkkonen et al. 2001). These 
regions are enriched by the expression of α6, α4, and δ subunits (Wisden et al., 1992; Pirker et al., 
2000). By expressing different subunit combinations in HEK cells, it has been shown that α6βx (but 
not α6βxγ2) receptors retain about 50% of the [35S]TBPS binding in the presence of millimolar 
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GABA concentrations (Korpi and Lüddens, 1993). As previous electrophysiological data on 
recombinant receptors have suggested that GABA is a partial agonist as compared to gaboxadol in 
extrasynaptic α6β3δ, 4β3δ and α4β3 receptors but not in α1-6β3γ2 receptors (Adkins et al., 2001; 
Ebert et al., 2001; Storustovu and Ebert, 2006) and as GABA-insensitive (GIS)-[35S]TBPS binding  
has been associated with α6β2/3 and α4/6β2/3δ receptors (Korpi and Lüddens, 1997; Mäkelä et al., 
1997; Korpi et al., 2002b; Sinkkonen et al., 2001, 2004a and 2004b), our hypothesis was that as a 
stronger agonist than GABA, gaboxadol at high concentration would displace the GIS-[35S]TBPS 
binding from α6β2/3 and α4/6β2/3δ receptors and if so, GIS-[35S]TBPS binding would indeed 
represent partial agonism of GABA on α6β2/3 and α4/6β2/3δ receptors. 
In line with the results of Sinkkonen et al. (2004b), the hippocampus of the Thy1α6 mice retained 
significantly more GIS-[35S]TBPS binding  (13.5 ± 1.0% of the basal [35S]TBPS binding)  than that 
of the control C57BL/6NHsd mice (1.7 ± 0.2% of the basal [35S]TBPS binding) revealing the α6βx 
receptors. Gaboxadol (1mM) displaced the [35S]TBPS binding  more than GABA (10 mM) in the 
hippocampus of the transgenic mice whereas the efficacies of GABA and gaboxadol were similar in 
the hippocampus of the wild-type control mice indicating that GABA is a partial agonist in 
comparison to gaboxadol in the α6βx receptors. As a characteristic of partial agonists is that they 
can reverse the effects of full agonists acting as competitive antagonists, we co-applied different 
doses of GABA with gaboxadol (1mM) and measured the remaining [35S]TBPS binding.  Already 
0.1 mM GABA significantly increased [35S]TBPS binding  as compared to gaboxadol alone, and 1 
mM GABA increased the [35S]TBPS binding  to the same level as saturating GABA concentration 
(10 mM) alone, demonstrating a competitive displacement of full agonist gaboxadol from the 
agonist binding site by the partial agonist GABA.  
The next question was whether a similar fingerprint for partial agonism of GABA could be found in 
the cerebellar granule cell layer and thalamus that are naturally expressing α6, α4, and δ subunits. In 
the Thy1α6 mice and control C57BL/6NHsd mice, a saturating concentration of GABA (10 
mmol/L) revealed a GIS-[35S]TBPS binding in the thalamus and cerebellar granule cell layer as 
expected. In both brain regions and mouse strains, gaboxadol displaced the [35S]TBPS binding more 
than GABA, and when increasing concentrations of GABA were co-applied with 1 mmol/L 
gaboxadol, GABA at millimolar concentrations increased [35S]TBPS binding in the transgenic and 
wild-type mice. However, in the thalamus and cerebellar granule cell layer, the difference between 
GIS-[35S]TBPS and gaboxadol-insensitive [35S]TBPS binding at high agonist concentrations was 
not as great as in the hippocampus of the transgenic mice, indicating that the efficacy difference 
between GABA and gaboxadol is greater in α6β3 receptors than in α6β3δ or α4β3δ receptors. These 
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results demonstrate that GIS-[35S]TBPS binding reflects partial agonism of GABA also in the native 
brain regions containing α6β3δ or α4β3δ receptors in which gaboxadol acts with higher efficacy. 
The collicular region was used as a control region because it expresses mainly α1βxγ2 receptors 
(Wisden et al., 1992; Pirker et al., 2000). These receptors represent the majority of GABAA 
receptors in the brain (Fritschy et al., 1992) and in these receptors gaboxadol acts as a partial 
agonist (Ebert et al., 1994; Ebert et al., 1997). In accordance with this, GABA was more efficient 
than gaboxadol in the collicular region of both mouse lines leaving no GIS[35S]TBPS binding at 
saturating GABA concentrations.  
Altogether, these results indicate that GIS-[35S]TBPS binding can be used as a fingerprint for partial 
agonism of GABA. 
5.7 Highly potent GABA is a partial agonist as compared to gaboxadol in α6β3, 
α6β3δ and α4β3δ receptors but not in α6β3γ2 receptors (II) 
The aim of this study was to investigate further the pharmacology of gaboxadol and GABA on 
different extrasynaptic GABAA receptors, namely on α6β3, α6β3δ, α4β3δ and α6β3γ2 receptors and 
to confirm that the GIS[35S]TBPS binding reflects the partial agonism of GABA as compared to 
gaboxadol in α6β3, α6β3δ and α4β3δ receptors. Gaboxadol had been earlier reported to act as a 
superagonist in recombinant α4β3δ receptors (Adkins et al., 2001). Later on, it was also shown that 
GABA is a partial agonist as compared to gaboxadol in human α4β3δ and α6β3δ receptors 
expressed on Xenopus oocytes and when GABA was co-applied with a fixed concentration of 
gaboxadol at α4β3δ receptors, GABA reduced concentration-dependently the response to gaboxadol 
until the response corresponded to the maximum response to GABA (Storustovu and Ebert 2006).  
In the present study the relative efficacy and other kinetic parameters of high concentrations of 
GABA (1 mmol/L) and gaboxadol (1 mmol/L) were studied in α6β3, α6β3δ, α6β3γ2 and α4β3δ 
receptors.  
Our electrophysiological results showed that gaboxadol had the highest relative efficacy as 
compared to GABA in α6β3 receptors, but also in α6β3δ and α4β3δ receptors the efficacy of 
gaboxadol was about twofold higher than that of GABA. This is in line with the previous 
electrophysiological data on recombinant receptors on α6β3δ and 4β3δ receptors (Adkins et al., 
2001; Ebert et al., 2001; Storustovu and Ebert, 2006). In α6β3γ2 receptors, the efficacy of GABA 
and gaboxadol were similar. However, the maximal GABA and gaboxadol-mediated currents via 
these receptors were much larger than those via α6β3, α6β3δ or α4β3δ receptors.  As partial 
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agonists reverse the effects of full agonists acting as competitive antagonists, we compared the 
effects of increasing competing concentrations of GABA on the maximal responses evoked by 1 
mmol/L gaboxadol and the effects of competing concentrations of gaboxadol on the maximal 
responses evoked by 1 mmol/L GABA in α6β3γ2 and α6β3δ receptors. As expected, in α6β3γ2 
receptors the efficacy of GABA and gaboxadol were identical, and the co-application of the 
competitor did not change the maximal response evoked by either GABA or gaboxadol. However, 
in α6β3δ receptors GABA reduced the 1 mmol/L gaboxadol response and gaboxadol increased the 
1 mmol/L GABA response. This interaction proves the partial agonism of GABA in the α6β3δ 
receptors.  
The weighted time constant for desensitization of α6β3γ2 receptors was similar for GABA (1 
mmol/L) and gaboxadol (1 mmol/L), and although α4β3δ receptors desensitized somewhat faster 
after GABA than after gaboxadol, both α6β3γ2and α4β3δ receptors showed largest extent of 
desensitization relative to the peak current at 4 s of both GABA and gaboxadol application. GABA 
and gaboxadol displayed most dissimilar kinetics in α6β3 and α6β3δ receptors which were 
desensitizing significantly faster after gaboxadol than after GABA application. Also the level of 
desensitization relative to the peak current at 4 s was greater after gaboxadol than after GABA in 
these receptors. In α6 subunit-containing receptors the deactivation after GABA was slowest in 
α6β3 receptors, followed in order by α6β3δ and α6β3γ2 receptors. The order of deactivation was the 
same after gaboxadol, and in all α6 subunit-containing receptors the deactivation occurred faster 
after gaboxadol than after GABA exposure. The relatively short deactivation time was similar after 
GABA and gaboxadol in α4β3δ receptors. 
The effects of high agonist concentrations reported here may not be physiologically important for 
the extrasynaptic currents, but they may explain the different effects of the agonists on the 
[35S]TBPS binding to native receptors. As the GIS-[35S]TBPS binding is imaged in the presence of 
high concentrations of GABA in α6β and α4/6βδ receptors (Sinkkonen et al., 2001), the partial 
agonism of GABA at these receptors correlates with GIS-[35S]TBPS binding. The partial agonism 
of GABA and superagonism of gaboxadol correlates also with the GIS-[35S]TBPS binding  that was 
dissociated to large extent by gaboxadol in the hippocampus of the Thy1α6 mice as well as in the 
thalamus and cerebellar granule cell layer of the wild-type mice, the regions known to express α6β, 
α4βδ or α6βδ receptors, respectively.  
Also the desensitization characteristics of the receptor complex may regulate the remaining agonist-
insensitive [35S]TBPS binding component. In the present study on recombinant α6β3, α4βδ3, α6β3δ 
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and α6β3γ2 receptors, GABA and gaboxadol did not differ in their speed of desensitization 
(measured as weighted time constant of desensitization) in α6β3γ2 receptors whereas it was always 
faster after gaboxadol exposure than after GABA exposure in the α6β3, α4β3δ, α6β3δ  receptors. 
The extent of desensitization (relative to the peak current of the tested agonist) or weighted time 
constant of deactivation did not provide evidence of different effect between GABA and gaboxadol 
at the α6β3γ2 receptors as compared to the α6β3, α4β3δ, α6β3δ receptors. If the speed of 
desensitization played a role in agonist-insensitive [35S]TBPS binding, logically thinking GABA 
would displace [35S]TBPS more than gaboxadol from α6β3, α4β3δ, α6β3δ receptors (opposite to 
what has been observed) due to its slower desensitization speed at these receptors. As the 
desensitization and deactivation kinetics were tested after a 4 s incubation, there is no data on how 
these kinetic parameters may change within the 90-minute incubation time in the [35S]TBPS 
binding studies. As a conclusion, more data is needed to reveal whether the desensitization kinetics 
of the receptor complex regulate the agonist-insensitive [35S]TBPS binding. 
5.8 The α6 subunit-containing GABAA receptors are widely distributed in the 
Thy1α6 mice (III) 
The α6 subunit mRNA expression was restricted to the cerebellar granule cell layer in the wild-type 
mice, in line with its known distribution (Laurie et al., 1992; Wisden et al., 1992), whereas in the 
Thy1α6 mice the α6 expression was widely distributed, including deeper layers of the isocortex 
(e.g. Cg1, motor, primary somatosensory, auditory and association areas), the olfactory areas 
(piriform area, anterior olfactory nucleus), hippocampal formation [CA1 and CA3 pyramidal cell 
layers, dentate gyrus (DG)] and BLA, being highest in the BLA, hippocampus and cortical regions. 
The receptor autoradiography revealed α6β and/or α6βδ receptors in the BLA and CA1 of the 
Thy1α6 mice as gaboxadol dissociated the [35S]TBPS binding significantly more than GABA. The 
diazepam-insensitive [3H]Ro 15-4513 binding, illustrating the localization of the ectopic α6βγ2 
receptors, was strong in the middle and deep layers of isocortex, olfactory areas (piriform area, 
anterior olfactory nucleus), hippocampal formation (CA1 and DG) and BLA in the Thy1α6 mouse 
brain. Similar levels of the diazepam-insensitive [3H]Ro 15-4513 binding  were present in the 
cerebellar granule cell layer of both wild-type and transgenic mice containing native α6βγ2 
receptors. 
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5.9 Widespread neuronal activation associated with gaboxadol-induced anxiolysis 
(III)  
The induction of c-Fos, a protein product of a c-fos immediate early gene, is used as a tool to 
identify brain cells that become activated in response to various stimuli (Kovács, 1998). The 
expression of c-Fos is rather low in the brain of naive animals (Ryabinin et al., 1999). However, 
injection and handling stress has been shown to significantly increase c-Fos expression in C57BL/6 
mice and a prehandling has been suggested as necessary to habituate the mice to the injection and 
handling stress and to decrease the c-Fos expression closer to the basal levels (Ryabinin et al., 
1999). In the present study c-Fos expression was studied two hours after saline of gaboxadol 
injection (3 mg/kg, i.p.) in the transgenic Thy1α6 mice and wild-type C57BL/6HNsd control mice. 
The tested gaboxadol dose had been shown to be highly anxiolytic in Thy1α6 mice whereas only 
slight anxiolytic-like behavior was observed in the C57BL/6HNsd control mice. It was assumed 
that the anxiolytic dose of gaboxadol mediated the enhanced behavioral response in Thy1α6 mice 
by activating the artificially located α6β and α6βγ2 receptors in the forebrain. We prehandled the 
mice to avoid the injection and handling stress-induced c-Fos expression before gaboxadol fully 
entered the brain (30-60 min) (Cremers and Ebert, 2007) in order to investigate possible sites of 
action of low anxiolytic gaboxadol dose in the Thy1?6 mice as compared to basal c-Fos levels. We 
expected that gaboxadol would decrease any basal c-Fos expression due to its inhibitory 
GABAergic mode of action and because the anxiolytic effect of benzodiazepines has been generally 
associated with a decreased neuronal activity (Beck and Fibiger, 1995; Panhelainen and Korpi, 
2012; Lkhagvasuren et al., 2014). It may be argued that our conditions with low level of 
stress/novel stimuli favored observations of only increases in neuronal activity whereas a decrease 
in already low basal c-Fos expression would have been difficult to detect. However, after saline 
injections, c-Fos was expressed at such levels in many regions that it should have been possible to 
detect increased inhibition (decreased c-Fos expression). Furthermore, in Lkhagvasuren et al. 
(2014), in many brain regions of non-stressed rats, including cerebral cortices (orbital, primary 
somatosensory, visual, secondary cingulate, retrosplenial and layer II piriform cortices and anterior 
olfactory nucleus), hippocampal formation, LS, claustrum, cortical and medial amygdaloid nuclei, 
posterior hypothalamic area, dorsal and medial premammillary nuclei, rhomboid nucleus of 
thalamus, superior colliculus and median raphe nucleus, diazepam was shown to decrease c-Fos 
expression approximately to half of the expression in the vehicle-treated rats, and similarly, 
diazepam decreased c-Fos expression in these regions in stress-exposed rats as compared to stress-
exposed vehicle-treated rats. 
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In contrast to our hypothesis, we observed an increased c-Fos expression in gaboxadol-treated 
Thy1?6 mice especially in the limbic areas, such as the cingulate cortex, septal nuclei and in the 
central extended amygdala areas, including BNST and CeA as well as in BLA. C-Fos was also 
increased in dorsal tenia tecta, medial anterior olfactory nucleus, and dorsal endopiriform nucleus of 
the gaboxadol-treated Thy1α6 mice. Interestingly, many of these regions have previously shown 
decreased c-Fos expression in non-stress-exposed as well as in stress-exposed rats after diazepam 
injection (Lkhagvasuren et al., 2014). In addition, several studies suggest that different stressors 
activate the medial prefrontal cortex (mPFC), cingulate cortex, BLA, BNST and LS, and it has been 
suggested that the threshold for c-Fos induction in these areas is low (reviewed in Kovács, 1998). 
As we anyway had earlier observed a reduced anxiety at the tested dose of gaboxadol (II), our 
findings on widely increased c-Fos expression was surprising. Gaboxadol had only limited effects 
on the c-Fos expression in the wild-type mice. In the lateral part of the mediodorsal thalamic 
nucleus (MDL), there was a significant increase in c-Fos expression only in the gaboxadol-treated 
wild-type mice, but not in the transgenic mice. In some brain regions, including hippocampal CA1 
and CA3 areas as well as layers 2-4 of the primary motor cortex, gaboxadol induced c-Fos 
expression regardless of the genotype.  
5.10 Potential mechanisms of paradoxical gaboxadol-induced widespread neuronal 
activation 
The gaboxadol-induced c-Fos expression may result from disinhibition of selected neuronal 
networks, although also depolarizing responses have been generated by GABAA receptor activation 
in a mature brain slices, and these depolarizing responses were originally proposed to be mediated 
via the activation of extrasynaptic GABAA receptors (Alger and Nicoll, 1979; Andersen et al., 
1980; Alger and Nicoll, 1982). In rat hippocampal slices an intense stimulation of GABAA 
receptors on distal dendrites produced a hyperpolarizing membrane potential response followed by 
a slow depolarizing potential (Staley et al., 1995). It was proposed that this depolarization was a 
result of activity-dependent collapse of the opposing concentration gradients of chloride and 
bicarbonate, and that this consequently diminished the voltage-dependent block of the NMDA 
receptors thereby further depolarizing the cell membrane (Staley et al., 1995). It has also been 
postulated that the KCC2-dependent increase in extracellular potassium ion transients ([ K+]o) cause 
an inward potassium ion current that induces a long-lasting and a more positive membrane potential 
than EGABA-A in CA1 pyramidal cells (Kaila et al., 1997; Smirnov et al., 1999; Viitanen et al., 2010). 
However, these depolarizing actions of GABAA receptors may well not be exclusive or even 
inclusive properties of extrasynaptic GABAA receptors and if such effects were occurring in vivo, it 
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would be likely that also diazepam would induce increased c-Fos expression. In addition, acute 
effects of systemic drugs with preferential action on extrasynaptic GABAA receptors, including 
gaboxadol, were not affected in mice lacking 80-85% of KCC2, although the responses to the 
synaptic GABAA receptor agonist benzodiazepine diazepam were strongly blunted (Tornberg et al., 
2007), suggesting that KCC2 is predominantly involved in the phasic but not in the tonic component 
of GABAergic neurotransmission.  
Methyl-6,7-dimethoxy-4-ethyl-beta-carboline-3-carboxylate (DMCM) is a potent inverse agonist in 
α1 subunit-containing receptors (Crestani et al., 2002), and a partial agonist in α6 subunit-
containing receptors (Knoflach et al., 1996; Saxena and Macdonald, 1996). Interestingly, the 
Thy1α6 mice have been shown to be more sensitive to DMCM-induced convulsions than the wild-
type mice (shorter latency to writhing clonus) (Sinkkonen et al., 2004b) indicating that Thy1α6 
mice are more susceptible to convulsions induced by the inverse agonism of DMCM on α1 subunit-
containing receptors and/or that agonism of DMCM on α6 subunit-containing receptors generates 
directly or indirectly shortened latency to neuronal excitation. Reduced synaptic GABAA receptor 
currents have been reported in the hippocampal CA1 neurons of Thy1α6 mice (Wisden et al., 2002), 
and therefore it seems likely that the Thy1α6 mice would be more sensitive to the convulsive effect 
of DMCM by decreasing the inhibitory effect of the receptors with an already reduced synaptic 
inhibition. It would be still an open question whether the agonism of DMCM on α6 subunit-
containing receptors could generate directly or indirectly neuronal depolarization or whether the 
increased extrasynaptic inhibition was just not sufficient to balance the decreased synaptic 
inhibition.  
Also the non-selective GABAA receptor blocker picrotoxinin shortened the latency of Thy1α6 mice 
to generalized convulsions as compared to wild-type mice (Sinkkonen et al., 2004b), which most 
likely resulted from reduced synaptic GABAA receptor responses. Picrotoxinin blocks also α6 
subunit-containing receptors, but since these receptors were not present in the forebrain of the wild-
type mice it is likely that the increased sensitivity to convulsions was due to blockage of already 
reduced synaptic GABAA responses in the transgenic mice. The result also suggests that 
physiological GABA concentrations are not sufficient to depolarize neurons via extrasynaptic α6 
subunit-containing receptors as blocking this response would have had an opposite effect on the 
convulsion sensitivity of the Thy1α6 mice.  
Tiagabine, an antiepileptic GABA uptake inhibitor increasing brain GABA levels, delayed 
picrotoxinin-induced convulsions at a low dose of 3.2 mg⁄ kg in Thy1α6 mice but not in the wild-
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type mice, but higher tiagabine doses shortened the convulsion latency in the Thy1α6 mice as 
compared to the wild-type mice (Sinkkonen et al., 2004b). This switch in the sensitivity of Thy1α6 
mice to the tiagabine-reduced convulsions may be due to the function of highly potent but low-
efficacy α6β3 receptors that at lower GABA concentrations would mediate the enhanced sensitivity 
of the Thy1α6 mice to tiagabine. At higher tiagabine concentrations causing higher extracellular 
GABA concentrations, the fully functioning synaptic GABAA receptors of wild-type mice with 
lower GABA sensitivity but higher efficacy would overcome the power of low efficacy α6β3 
receptors and reduced synaptic inhibition in the Thy1α6 mice, thereby mediating the more enhanced 
antiepileptic response to high-dose tiagabine in the wild-type mice. An alternative explanation 
could be that at higher tiagabine concentrations an intense activation of extrasynaptic GABAA 
receptors by GABA resulted in depolarizing responses in the transgenic mice. In support of the 
latter, enhanced tonic GABAA receptor conductance via the knock-down of GABA reuptake has led 
to ataxia, tremor and increased nervousness (Chiu et al., 2005) suggesting increased neuronal 
excitation following increased extrasynaptic GABAA receptor function, but this neuronal excitation 
could also be an indirect effect of increased inhibition of inhibitory interneurons. Some reports have 
suggested that increased tonic inhibition of cortical interneurons by gaboxadol can lead to increased 
cortical network excitability (Krook-Magnuson and Huntsman 2005, Drasbek and Jensen 2005).  
Overall, the direct gaboxadol-induced depolarization is an unlikely mechanism for the paradoxical 
c-Fos induction in the Thy1α6 mice because the hippocampal principal neurons were not 
increasingly activated by gaboxadol in the transgenic Thy1α6 mice, although the CA1 neurons 
express high level of ectopic and functionally active ?6?/?2 receptors (Wisden et al., 2002; 
Sinkkonen et al., 2004b). Furthermore, c-Fos induction by gaboxadol treatment in Thy1α6 brain 
was not restricted to areas highly expressing the α6-containing GABAA receptors (such as BLA and 
medial anterior olfactory nucleus) suggesting that indirect pathways lead to the paradoxically 
widespread activation. For example in the CeA and septum, gaboxadol induced strong c-Fos 
expression in spite of the lack of ectopic α6 subunit expression. 
Altogether these results demonstrate that the anxiolytic dose of gaboxadol, preferring ?4, ?6 or 
??subunit-containing extrasynaptic receptors, paradoxically activates multiple neurons in the limbic 
brain regions via α6 subunit-containing GABAA receptors in the Thy1α6 mice. This suggests that 
the widespread neuronal inhibition as typically associated with benzodiazepines is not the exclusive 
mechanism of anxiolysis. Instead, the selective activation of certain neuronal populations in the 
amygdala and BNST, might specifically lead to strong anxiolytic responses in the Thy1α6 mice. 
68 
 
5.11 Gaboxadol activated neurons in mediodorsal thalamic nucleus only in wild-
type mice 
MDL differed from the other brain regions, because there a significant increase in c-Fos expression 
was found only in the gaboxadol-treated wild-type mice, but not in the transgenic mice. MDL is 
interconnected with the mPFC and amygdala, being a part of the limbic circuitry (Vertes, 2006), 
and involved in fear-related information processing (Lee et al., 2012; Padilla-Coreano et al., 2012) 
and anxiety (Farb and Ratner, 2014).  It has been shown recently, that a direct gaboxadol injection 
into the MDL, naturally containing gaboxadol-sensitive extrasynaptic α4βδ GABAA receptors 
(Cope et al., 2005; Jia et al., 2005; Richardson et al., 2013), increased fear freezing and attenuated 
fear extinction (Paydar et al., 2014). This suggests that local inhibition of MDL neurons mediate 
anxiety rather than anxiolysis.   
As in our behavioral study (II), the low dose of gaboxadol was anxiolytic in Thy1α6 mice but not in 
the wild-type mice, it is tempting to speculate that in the transgenic mice, gaboxadol counteracted 
the anxiety mediating local action in MDL via α6 subunit-containing receptors outside MDL as no 
ectopic α6 subunit-containing GABAA receptors were observed in the MDL. However, as a result it 
would be expected that c-Fos was rather decreased than increased in the wild-type mice as 
compared to the Thy1α6 mice if gaboxadol did not induce direct α4βδ GABAA receptor-mediated 
depolarization. Histologically two populations of neurons, small inhibitory GABAergic 
interneurons projecting restrictedly to specific thalamic nuclei and larger excitatory relay neurons 
projecting to the cerebral cortex, have been described for the mediodorsal thalamic nucleus 
(Damgaard Nielsen et al., 2008). More detailed information on the activated neuronal MDL 
subpopulations and their association with gaboxadol-sensitive receptors would be necessary in 
order to understand the role of MDL in the anxiolytic action of gaboxadol in Thy1α6 mice.  As a 
strong expression of ectopic α6 subunit-containing GABAA receptors was observed in the BLA as 
well as in the deep layers of PFC, both of which are abundantly projecting to the MDL (Vertes, 
2006), these projections in the Thy1α6 mice may have inhibited the neuronal activation in the MDL 
that was observed in the wild-type mice after gaboxadol treatment.  
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6 Conclusions 
GABAA receptors and neuroanatomy of anxiety have been widely studied over decades. By 
utilizing human brain tissue and taking the advantage of a unique mouse model, this thesis 
work provides new information on GABAA receptor pharmacology and on brain structures and 
mechanisms that may mediate anxiolytic responses via specific types of GABAegic inhibition: 
1. Previously, contradictory reports had been published in regard to the expression and 
participation of the γ2 subunit in the functional GABAA receptors in the rodent LC. 
(Fritschy et al., 1992; Lüddens et al., 1995; Caldji et al., 1998 and 2000; Araki et al., 1992; 
Luque et al., 1995; Tohyama and Oyamada, 1994; Chen et al., 1999). Our results show that 
in human, the γ2, α1 and α2/α3 subunits are expressed in the LC neurons. These findings 
indicate that the human LC may directly mediate the sedative and anxiolytic effects of 
benzodiazepines. 
 
2. Systemic gaboxadol acts preferentially via ectopically expressed α6β/γ2 receptors as 
compared to naturally occurring GABAA receptor subunit combinations in the forebrain, as 
the transgenic mice overexpressing these receptors were significantly more sensitive to the 
anxiolytic and hypnotic effects of 3 and 25 mg/kg of gaboxadol, respectively. This 
transgenic mouse model provides unique information on the pharmacology of gaboxadol in 
vivo. 
 
3. GABA-insensitive (GIS) [35S]TBPS autoradiographic signal reflects partial agonism of 
GABA because gaboxadol  as a stronger agonist than GABA displaced the  GIS-[35S]TBPS 
binding from α6β2/3 and α4/6β2/3δ receptors at saturated concentrations. As a result, GIS-
[35S]TBPS binding can be used as a fingerprint for partial agonism of GABA. 
 
4. GABA is a partial agonist as compared to gaboxadol in typically extrasynaptic α6β3, α6β3δ 
and α4β3δ receptors but not in α6β3γ2 receptors. Gaboxadol and GABA display also 
different receptor desensitization and deactivation kinetics in these receptors suggesting a 
different transduction pathway leading from agonist binding to gating of the extrasynaptic 
ion channel.  
 
5. Gaboxadol acting preferentially via extrasynaptic GABAA receptors induced a widespread 
neuronal activation rather than inhibition in many brain areas of the transgenic Thy1?6 
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mice overexpressing the GABAA receptor ?6 subunit. Although the ?6 subunit is expressed 
outside its natural environment in the Thy1?6 mouse model, the model demonstrates how 
neuronal excitability can be altered in different brain regions as a consequence of enhanced 
tonic inhibition in specific forebrain structures. In many areas this neuronal activation was 
likely to be an indirect network effect, but in some areas (e.g. BLA, anterior olfactory 
nucleus) the neuronal activation occurred in the areas containing extrasynaptic GABAA 
receptors. Slow depolarizing potentials have been reported after an intense stimulation of 
GABAA receptors on distal dendrites of rat hippocampal slices and after an initial 
hyperpolarizing membrane potential (Staley et al., 1995). The transgenic Thy1?6 mouse 
model could be an interesting tool to study whether the extrasynaptic ?6 subunit-containing 
GABAA receptors may function also as excitatory rather than only inhibitory receptors in 
adult mice.  
 
6. The widespread neuronal inhibition as typically associated with benzodiazepines may not 
be the exclusive mechanism of anxiolysis. We observed an increased neuronal activation 
especially in the limbic areas of Thy1α6 mice after an anxiolytic dose of gaboxadol.  
However, future experiments are needed to demonstrate the actual causality between the 
neuronal activation and anxiolysis. In addition, as brain areas are built of different neuronal 
subpopulations that are connected in a complex network, it is also important to study the 
neuronal activation/inactivation at a cellular and sub-cellular level to understand the 
mechanism of anxiolysis in more detail and to further be able to develop more selective and 
safe treatments to anxiety disorders.  
 
7. Unconditioned approach-avoidance conflict tests such as the elevated plus-maze and 
light/dark exploration test are considered to model some components of human anxiety 
disorders. However, the fear conditioning tests are likely to be more valid, as regards 
especially the construct validity, in studying the neuroanatomy and mechanisms of anxiety 
disorders as they involve the fear learning component that is dysregulated in anxiety 
disorders.  
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